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ABSTRACT 
 
 
 Neuraminidase (NA) inhibitors including oral oseltamivir and inhaled zanamivir 
are among the first line of defense against influenza virus infection. Development of 
resistance to NA inhibitors is a huge drawback for limited options for the control of 
influenza. During the first decade of NA inhibitor use, the detection rates of resistance to 
both NA inhibitors had remained low in circulating influenza viruses. However, the 
2008~2009 season was marked by a radical increase of prevalence of oseltamvir 
resistance from <1% to >90% in worldwide surveillance in less than a year. The 
resistance was solely linked to NA H275Y variants of seasonal H1N1 viruses, and they 
are referred as the naturally resistant viruses. A big question remains open about what 
fundamental molecular changes in the seasonal H1N1 viruses led to the surge of the 
naturally resistant viruses. When this question remained pending, a novel swine-origin 
H1N1 influenza virus emerged in Mexico at April 2009, soon spread worldwide 
replacing the seasonal influenza viruses including the naturally resistant viruses, and 
marked 2009 with the first influenza pandemic of the 21st century. With sustainably 
increased worldwide use of NA inhibitors especially oral oseltamivir during the 
pandemic, the oseltamivir-resistant variants carrying H275Y NA mutation were isolated 
at low incidence from individuals receiving oseltamivir treatment and a few community 
clusters. In view of the high prevalence of naturally resistant seasonal H1N1 viruses in 
the immediate preceding season, there was an urgent need to characterize the 
transmissibility and fitness of oseltamivir-resistant pandemic H1N1/2009 viruses, 
although the resistance rates have remained low so far. 
 
We first addressed the urgent question about pandemic viruses by investigating 
the transmissibility of a closely matched pair of pandemic H1N1/2009 clinical isolates, 
which only differed at the H275Y NA mutation in their genome, in the ferret model. We 
found that the H275Y NA mutant H1N1/2009 virus was not transmitted efficiently in 
ferrets via respiratory droplets, while it retained efficient transmission via direct contact. 
The wild-type H1N1/2009 virus was efficiently transmitted via both routes. The 
wild-type and the mutant viruses appeared to cause a similar disease course in ferrets 
without apparent attenuation of clinical signs. In the growth competition in a ferret, the 
H275Y mutant virus showed less growth capability than the wild-type virus. The NA of 
the H275Y mutant virus showed reduced substrate-binding affinity and catalytic activity 
in vitro and delayed initial growth in MDCK and MDCK-SIAT1 cells. These findings 
may in part explain its less efficient transmission. The fact that the oseltamivir-resistant 
H1N1/2009 virus retained efficient transmission through direct contact underlines the 
necessity of continuous monitoring of drug resistance and characterization of more NA 
inhibitor-resistant variants of the pandemic H1N1 viruses. 
 
We also sought to resolve the pending question about the naturally resistant 
seasonal H1N1 viruses by investigating the changes of different seasonal H1N1 viruses in 
terms of NA genetics, NA proteins attributes and virus fitness. We found that during the 
seasonal H1N1 virus evolution, two genetically diverged lineages of H1N1 viruses were 
circulating at different times. The NA protein phenotypes of the two lineages were 
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naturally distinct in the levels of protein expression and enzyme affinity, and accordingly, 
the H275Y NA mutation had differential effects on the NA proteins and virus fitness of 
the two lineages. The new lineage NA proteins were inherently higher in protein 
expression and enzyme affinity than the old lineage NA proteins and thus were able to 
tolerate the negative effects of the H275Y mutation with a marginal loss of enzyme 
activity. As a result, the H275Y mutant H1N1 viruses of the new lineage had virus fitness 
equivalent to the wild-type viruses and were able to continue circulating, becoming the 
naturally resistant viruses. Further study revealed that 4 different amino acid substitutions 
played different roles in maintaining high protein expression and enzyme affinity of the 
new lineage NA proteins; the timeline of the sequential acquisition of the 4 substitutions 
was consistent with the timeline of emergence of the naturally resistant H1N1 viruses. 
The identified NA tolerance to the H275Y mutation in the naturally resistant seasonal 
H1N1 viruses also had implication on the virus fitness of the H275Y mutant H1N1/2009 
viruses, as well as on the continuing surveillance monitoring of circulating pandemic 
H1N1 viruses. 
 
Overall, both studies investigated in vitro and in vivo fitness of H275Y mutant 
H1N1 viruses relative to their respective wild-type viruses, which were circulating in 
human beings at different times. These studies correlated the viral fitness of the H275Y 
mutant viruses with the NA tolerance to the H275Y mutation at protein level, and 
revealed that the NA tolerance to the H275Y mutation was the molecular determinant of 
fitness of H275Y mutant H1N1 viruses. The studies have implications on surveillance 
monitoring of the NA inhibitor resistance in circulating influenza viruses, which 
underlines the necessity of continuous monitoring of drug resistance incidence, as well as 
potential genetic and phenotypic changes of constantly evolving influenza viruses.  
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CHAPTER 1.    GNERAL INTRODUCTION - NEURAMINIDASE INHIBITOR 
RESISTANCE IN INFLUENZA A VIRUSES: MOLECULAR MECHANISM 
AND VIRUS FITNESS 
 
 
Influenza Viruses and Influenza Disease 
 
Influenza viruses are among the most important human-inflicting pathogens. 
Influenza viruses are enveloped viruses with single-stranded negative-sense segmented 
RNA genome, belonging to the members of the orthomyxoviridae family. Influenza 
viruses can be classified into A, B, C types. Human influenza viruses are mainly A and B 
type. Influenza B is separated into Yamagata and Victoria lineages. In influenza A 
viruses, two virus surface glycoprotein hemagglutinin (HA) and neuraminidase (NA) 
determine and differentiate their antigenic subtypes into 16 HA subtypes and 9 NA 
subtypes (1). All these influenza A subtypes can be found in their natural reservoir 
aquatic birds (2). Only three HA subtypes (H1, H2, H3) and two NA (N1, N2) subtypes 
have been found to cause efficient infection in human populations, including human 
H1N1, H2N2 and H3N2 subtype viruses. In addition, occasional human cases of the 
infection with avian influenza A viruses of H5, H7 and H9 subtypes have been 
reported (3-5). In circulating human influenza viruses, HA and NA surface proteins 
constantly evolve to escape the accumulated herd immunity pressure against the two 
proteins by acquiring mutations at their antigenic sites known as antigenic drift. In 
addition, the reassortment ability between two different influenza virus strains can 
generate a new strain of virus which possesses distinct surface proteins from their 
parental viruses, known as antigenic shift. 
 
Influenza viruses cause an acute contagious disease in the respiratory tracts -
influenza. Every year, human seasonal influenza viruses which are mainly co-circulating 
influenza A H1N1 and H3N2 subtypes and influenza B type, cause annual influenza 
epidemics. The typical clinical symptoms of human influenza virus infection include 
coughing, sneezing, sore throat and fever. Severe disease including pneumonia and other 
systematic symptoms are normally limited to the susceptible populations such as 
immunocompromised patients, young children and elderly people. Although the seasonal 
influenza outbreaks normally tend to be mild, they still cause thousands of deaths and 
millions of hospitalizations annually. Periodically, new strains of influenza viruses can 
emerge from different species and rapidly spread into human beings, causing world-wide 
outbreaks of infection - influenza pandemics. Historically, there are serious pandemics in 
the 20th century with numerous death caused by different influenza viruses H1N1, H2N2, 
and H3N2, respectively (2). Most recent example is the 2009 H1N1 influenza virus 
pandemic, the first pandemic in the 21st century caused by a novel swine-origin influenza 
virus of H1N1 subtype (6;7). The most confirmed human cases of H1N1/2009 influenza 
have been uncomplicated and mild, but the number of cases and affected countries was 
unprecedented. In addition, human infection of avian influenza viruses had variable 
clinical outcomes, with symptoms involving typical influenza symptoms and other, 
pneumonia, rhihnorrhea, diarrhea, hypoxemia and leucopenia systematic symptoms (8). 
The human cases of avian H5N1 influenza virus infection, which sporadically occurred at 
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South East Asia and Middle East Africa (9), are especially associated with extremely 
high mortality and morbidity. Although transmission of H5N1 influenza viruses from 
avian species to humans is currently inefficient, the novel antigenicity of the viruses for 
human populations and the highly fatal outcome of the infection raised huge concern 
about their potential to become the next pandemic virus and the severity of the potential 
pandemic.  
 
 
Structure and Replication of Influenza A Virus 
 
 Virion structure of influenza A virus. Virions of Influenza A virus are 
lipid-enveloped particles, typically displaying roughly spherical shape or long filament 
shape (1;10). The virions have three transmembrane proteins including two surface 
glycoproteins HA and NA and one membrane-embedded M2 protein. HA protein is the 
most abundant envelope protein (80%). They are rod-shaped trimer molecules with C 
terminus forming a membrane anchor inserted into viral membrane and N terminus 
forming a globular head projected away from viral surface like a spike. NA protein is the 
second major envelope protein (17%) and is cluster together as patches on the viral 
membrane. NA protein is mushroom-shaped tetramer molecule with a short N-terminal 
cytoplasmic tail and transmembrane region as anchor for the stalk and head. M2 protein 
has very minor abundance among envelope proteins and it is also a tetramer molecule 
which forms ion channels spanning the envelope. On the interior side of the virion lipid 
envelope, a matrix formed by M1 protein holds 8 viral ribonucleoprotein (vRNP) 
complexes in each virion. Each vRNP complex is made up of one RNA gene segment 
coated by nucleoproteins (NP) and associated with a polymerase complex of PB1, PB2 
and PA proteins. The virions also contain Nanostructure Protein 2 (NS2), sometimes also 
called nuclear export protein (NEP). The 8 genome segments of influenza A viruses 
encode for 10 viral proteins. Six segments encode HA, NA, NP, PB1, PB2, PA proteins 
respectively, and the mRNAs of 2 segments, M and NS segments can be alternatively 
spliced into M1/M2 and NS1/NS2 genes respectively. Among the 10 viral proteins, 
except for NS1 protein, other 9 proteins are incorporated into the virus particles during 
virus replication. In some influenza A viruses, the +1 reading frame of PB1 gene can 
encoded an additional protein PB1-F2 of up to 90 amino acid residues (11). PB1-F2 
proteins are truncated in some influenza A viruses, due to the frequent appearance of stop 
codon in the alternative reading frame of PB1 gene. Each protein function differently and 
concertedly during replication cycle of influenza A viruses.  
 
 Life cycle of influenza A virus.  Concisely, the replication cycle of influenza A 
virus in cells can be divided into several phases (10): virus entry into host cells, import of 
vRNPs into the nucleus, transcription and replication of viral genome, export of nascent 
vRNPs from the nucleus, assembly and budding of progeny virions, and finally release of 
the progeny viruses from infected host cell surface. Each phase is involved with multiple 
molecular events mediated by different host and viral factors and a lot of precise details 
in these events are still under investigation. 
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Influenza A virus replication start from the entry of virus particles into host cells. 
This phase is involved several steps including virus attachment, endocytosis of virus 
particle, fusion of viral envelope with endosomal membrane and uncoating of virus 
particle within endosome (1;10). The surface glycoprotein HA plays several different 
critical roles during these steps. The HA protein is synthesized as a single polypeptide 
precursor HA0. For most influenza viruses, the HA0 must be cleaved by host proteases 
into HA1 and HA2 subunits which are linked by disulphide bonds. HA1 subunit contains 
receptor binding domain, and HA2 subunit contains transmembrane domain and a fusion 
peptide. Influenza A virus entry starts from virus attachment to host cell surface by the 
interaction of the HA receptor binding domain with the sialic acid containing-receptors at 
host cell surface. Upon binding to the cell surface, the virus is internalized by 
receptor-mediated endocytosis. Being inside an endosome, the virus enters into the host 
cell. When the endosomal pH is decreased to ~5 by action of an H+ pump on the 
endosomal membrane, the low pH induce an irreversible confirmation change of the 
whole cleaved HA molecule, which expose and realign the fusion peptide in the HA2 
subunit. The realigned fusion peptide bring the viral and endosomal membranes into 
contact with each other and insert itself into the endosomal membrane. The action of 
more than two fusion peptides form the fusion pores in the membrane of the virion, 
enabling release of the content of the virion into cell cytoplasm. The acidic environment 
in the endosome also open M2 ion channels in the viral membrane, allowing the influx of 
H+ ions from endosome into the virion. The acidification of the virion disrupts vRNPs 
binding to M1 proteins, leading to the release the free vRNPs into cyctoplasma, which 
complete the uncoating process.  
 
 After the vRNPs are released into the cytoplasm, they are to be imported into the 
nucleus, where they serve as templates for transcription and replication of virus 
genome (1;10). All proteins in vRNP complex including NP, PB1, PB2 and PA possess 
nuclear localization signals (NLSs), which interact with cellular nuclear import 
machinery and mediate the vRNP import into nucleus. Once in the nucleus, in order for 
synthesis of the viral proteins, each negative-sensed RNA segment is transcribed into 
messenger RNA (mRNA), which is capped and polyadenylated positive-sensed RNA for 
protein translation. For replication of the viral genome, each negative-sensed RNA 
segment is firstly transcribed into an exact positive-sensed complementary RNA (cRNA) 
copy, then in turn the cRNA serve as template for synthesis of more copies of 
negative-sensed viral RNA (vRNA). All these transcription and replication of viral RNA 
segments are catalyzed by the same viral polymerase complex, an RNA-dependent RNA 
polymerase complex made up with three subunits PB1, PB2 and PA. The viral mRNAs 
are transported to the cytoplasm and serve as templates for translation of viral proteins. 
NS1 protein is believed to block the transportation of host cell mRNAs thus facilitating 
the viral mRNA process. Newly synthesized M1, NP and NS2 proteins are imported back 
into the nucleus for assembly and transportation of new vRNPs. Following virus 
replication, newly formed vRNPs are assembled in the nucleus and are to be exported 
into the cytoplasm. It is believed that M1 protein and NS2 protein are involved in this 
process by masking the NLS in the proteins of vRNPs and also interacting with nuclear 
export machinery respectively.  
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 After the vRNPs have been exported into cytoplasm, they are to be packed with 
other viral proteins into virus particles to leave the cells (1;10). This process occurs at the 
apical plasma membrane of polarized cells and involves with multiple events including 
assembly of different viral components, package of all 8 segments, membrane budding 
and release of nascent virons. The three transmembrane proteins are assembled into 
trimers (HA) or tetramers (NA and M2) in cell endoplasmic reticulum, and then they are 
directed to assembly sites and are further incorporated into cell membrane by the signals 
residing in the transmembrane domains of HA and NA proteins. Other viral components 
including viral segments also reach the assembly sites and are poised for virion budding. 
Virus budding is seen as the extrusion of cell membrane along with all the virus 
components in its inner core and eventual formation of virus particles after the fission 
from the cell membrane. M1 is believed as the driving force behind this process. After 
completion of virus budding, the virus particles are attached to the infected cell surface 
due to HA binding to the sialic acid-containing receptors, so the progeny virions cannot 
leave cell membrane without active release by the action of NA. The enzyme activity of 
NA proteins cleaves the sialic acid residues from glycoproteins and glycolipids on the 
cell membrane, thereby releasing the progeny virions into extracellular environment to 
infect new host cells.   
  
 
Influenza A Virus Molecular Determinants on Pathogenesis and Transmission 
 
 Each viral protein of influenza virus plays different and indispensable role in virus 
life cycle and they are tightly regulated and coordinated with host factors to cause an 
effective virus infection in a host. Primarily all the viral proteins contribute to successful 
infection of influenza A virus in hosts, although the precise action mechanism of each 
viral protein on the virus pathogenesis and transmission in hosts is still to be further 
explored. Studies of different subtype influenza A viruses of different properties have 
identified several dominant viral molecular determinants on virus pathogenesis and 
transmission (2;12;13).  
 
 Two major functions of HA protein, receptor-binding and fusion activity, both 
contribute to virus transmission and pathogenesis (2;12;13). Firstly, HA proteins have 
specificity for recognition of host cell receptors, making HA a determinant for influenza 
virus host range. Now, it is generally believed that HA proteins of human influenza virus 
isolates preferentially binds to ?2,6-linked sialic acids, while HA proteins of avain virus 
isolates preferentially binds to ?2,3-linked sialic acids (14). Mainly ?2,6-linked sialic 
acids are found in human upper respiratory tract, the primary site of influenza infection, 
which impose a restriction for efficient transmission of avain influenza virus into human 
beings. Accordingly, virus possession of HA recognizing human-type receptors is also 
seen as a pre-requisite for sustained human-to-human transmission of the virus. Secondly, 
HA precursor cleavage is essential for viral infectivity and cleavability of HA precursor 
is a restriction factor for effective virus replication. The HA proteins of most of influenza 
A viruses only posses a single Arg residue at the cleavage site, which must be cleaved by 
host cell proteases in respiratory or intestinal organs, thus the virus replication is 
restricted locally within these organs. In contrast, the HA proteins of highly pathogenic 
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H5 or H7 viruses possess multi-basic amino acids at the cleavage site (15), which allows 
their proteolytic cleavage by universal unbiquitous proteases during HA peptide 
post-translational modification and leads to severe systemic infection. Therefore, the 
multi-basic HA cleavage motif is seen as a virulence factor for influenza virus.  
 
 The replication capability of polymerase complex of influenza A virus contributes 
to virus pathogenicity by directly controlling virus growth in hosts. Several mutations 
such as E627K and D701N in PB2 subunit are associated with the polymerase replication 
ability, thus virus pathogenicity and transmission (2;12;13). PB2 E627K mutation in the 
avian H5N1 influenza viruses can enhance the polymerase replication ability in 33°C, but 
not at higher temperature 37ºC and 41°C (16). 33°C is the approximate temperature of 
mammalian upper respiratory tract where human influenza viruses replicate, whereas 
41°C is the approximate temperature of avian intestinal tract where avian influenza 
viruses replicate. Therefore, avian H5N1 influenza viruses with PB2 E627K mutation had 
increased pathogenicity in mammalians (17). In contrast, PB2 K627E mutation in the 
human influenza A viruses reduces virus transmission in mammalian animal models due 
to reduced replication in their upper respiratory tracts (18).  
 
 PB-1 F2 is a small protein of up to 90 amino acid residues encoded by an 
alternative reading frame of PB1 gene and it can be truncated at different lengths by 
different location of stop codon in the alternative reading frame. PB1-F2 preferentially 
localizes to mitochondria membrane in the infected cells and has a pro-apoptotic 
function (11). PB1-F2 also can enhance the virus polymerase activity in vitro (19). An 
S66N mutation in PB1-F2 mutation was found to be responsible for the high virulence of 
both 1918 pandemic and avian H5N1 influenza viruses (20). Therefore, PB1-F2 is also 
known as virulence factor of influenza viruses. 
 
 Pathogencity of influenza A viruses also depends on their ability to evade host 
immune response, especially the first line innate response as influenza viruses only cause 
acute infection. NS1 protein is found as an interferon antagonist to suppress host innate 
response to viruses (21). NS1 prevents activation of certain transcription factors thus also 
the following stimulation of interferon production. The NS1 proteins of highly 
pathogenic H5N1 viruses are associated with induction of high levels of 
pro-inflammatory cytokines in hosts, which was linked to the severe inflammation and 
high morbidity and mortality caused by the viruses (2;22). Several mutations such as 
D92E and P42S in NS1 protein of the H5N1 viruses have been linked to virus 
virulence (23;24).  
 
 The enzyme activity of NA function mainly functions to actively release progeny 
virus particles from infected cell surface. NA is also believed to function to cleanse the 
respiratory tract environment such as mucus and cell surface for virus entry by removing 
the sialic acid from host glycoproteins or glycolipids. In addition, NA also can prevent 
virus particle aggregation and allow virus spread (25). Efficient influenza A virus 
replication requires an optimal functional balance between HA sialic acid-binding 
activity and NA receptor-destroying activity. The balance can be disturbed by 
reassortment between different virus strains, interspecies transmission etc events and the 
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changes of function NA and their impacts on virus infectivity during these events have 
been described (26;27). Especially during antiviral treatment, influenza virus can adapt to 
NA inhibitor drugs by generation of resistant viruses of NA mutations. How these NA 
mutations cause resistance to NA inhibitors and how they affect NA function and fitness 
of the mutant viruses including virus pathogenesis and transmissibility is the focus of this 
review as discussed below. 
 
 
Interventions of Influenza Infection 
 
 
Vaccination and Antiviral Medication 
 
Vaccination is one of the effective interventions for influenza infection, primarily 
for preventing infection and reducing the morbidity and mortality associated with the 
influenza infection. Seasonal influenza vaccines, either the trivalent inactivated virus 
vaccine or the live attenuated virus vaccine include contemporary H1N1 and H3N2 
influenza A virus and influenza B as the three antigen components. The three antigen 
components have to be evaluated annually based on the contemporary prevalence of the 
circulating viruses, and are subject to reformulation when the antigenicity of prevalent 
circulating viruses changes. Thus, the efficacy of vaccination is largely determined by the 
matches between circulating viruses and selected vaccine strains and can be significantly 
reduced by mismatches. Additionally, the efficacy of vaccination is also limited by the 
adequacy of host immune response against the vaccine antigens, the complication of the 
pre-existing immunity mounted in individuals especially adults. More importantly, in the 
scenario of a pandemic which are caused by emergent influenza viruses with new 
antigentic features, there is considerable delay time, normally at least 6 months, before a 
sufficient amount of the new antigenically-matching vaccines can be produced.  
 
Thus, antiviral medication provides another option for the control and 
management of acute influenza infection. The goal of antiviral treatment is to decrease 
the disease associated symptoms, complications, mortality etc. Specific anti-influenza 
drugs have also been used for both prophylactic and therapeutic treatments of influenza 
infection during seasonal epidemics. Antiviral medication is particularly important at the 
beginning of a fast-spreading pandemic, and it is even likely to become the only first-line 
control strategy before the antigenically-matching vaccine is available. The beneficial 
effects by the antiviral medication on patients including reducing virus shedding duration, 
illness symptoms and functional disability caused by the illness, although the magnitude 
of the efficacy varies, depending on the drugs used, the populations treated, the viruses 
infected and the timing of the treatment initiation etc.  
 
 
Influenza Virus-specific Antiviral Drugs 
 
At present, there are two classes of FDA-approved antiviral drugs specific for 
influenza viruses, M2 blockers and NA inhibitors. M2 blockers including amantadine and 
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rimantadine were the earliest class of specific anti-influenza compounds. Amantadine 
was approved by FDA as early as at 1963 and rimantadine at 1993.  This class of drugs 
targets the M2 ion channel located in the viral membrane. Binding of the drugs in the 
channels blocks virus uncoating thus prevent its following replication inside the cell. M2 
blockers are only effective against influenza A virus. They are effective for prophylaxis 
and therapeutic treatments of influenza infection and exert clinic benefit including 
decreased duration of virus shedding and disease symptoms in patients (28). The 
resistance to M2 blockers are developed during treatment and conferred by amino acid 
residues changes in the M2 ion channel, most notably at S31N. The prevalence of the M2 
blocker resistance is a serious problem for this class of drugs: to date, it has been reported 
of  >90% resistance rate in seasonal H3N2 viruses, overall 15% rate in seasonal H1N1 
viruses, 100% rate in all characterized 2009 pandemic H1N1 viruses, and varied rates 
including as high as 90% in certain clades of avian H5N1 viruses (29) (30;31) . The 
high-level circulation and rapid spread of the resistant influenza viruses in the community 
have compromised the usefulness of the M2 blockers.  
 
Another class of specific influenza virus-specific antivirals is the NA inhibitors, 
including oral oseltamivir and inhaled zanamimir which were approved by US FDA at 
1999 for treatment of influenza infection (32). The third investigational NA inhibitor, 
peramivir developed as intravenous formulation, has been licensed only in Japan, but is 
in ongoing clinic trails in US now (28). Based on its promising efficacy, it was warranted 
by US FDA with an emergency use authorization for treatment of 2009 pandemic 
influenza virus infection in certain patients (33). NA inhibitors now are the first line of 
specific anti-influenza drugs due to the high prevalence of resistance to the M2 blockers 
in human influenza A viruses and the lack of activity against influenza B viruses of the 
M2 blockers. 
  
 
Mechanism of Action of NA Inhibitors 
 
NA inhibitors target the NA enzyme, one of the membrane glycoproteins 
presented at the surface of the influenza virus particle. Influenza virus NA functions to 
cleaves the ?-2,3- or ? -2,6-ketosidic linkage between a terminal sialic acid residue and 
an adjoining sugar residue (28;34). In the influenza virus replication cycle, by removing 
the sialic acids residues from the membrane surfaces of infected cells, NA destroys the 
association between infected host cells with HA proteins, thus facilitating the release the 
nascent viruses and allowing the progeny viruses to infect new host cells (28;34).  
 
All type/subtypes of influenza viruses have abundant NA proteins in their 
membranes, and the main structure and critical amino acid residue at the enzyme active 
site are highly conserved among all NA stubypes of influenza viruses, although the NA 
protein constantly evolves under immunity pressure and continuously changes the amino 
acid residue composition. 19 conserved residues were identified at the NA active site: 
including 8 catalytic residues (R118, D151, R152, R224, E276, R292, R371, and Y406; 
N2 numbering) which directly interact with the sialic acid substrate during the enzyme 
reaction, and 11 framework residues (E119, R156, W178, S179, D/N198, I222, E227, 
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H274, E277, N294, and E425) which support structure and function of the active 
site (35). NA inhibitors were all developed through rational drug designs based on the 
knowledge of the crystallographic structure of the NA complex with sialic acid (36;37). 
 
All three NA inhibitors, oseltamivir, zanamivir and peramivir are analogues of 
sialic acid, the natural substrate of the NA enzyme (36). NA inhibitors competitively bind 
to the NA active site, and thus block the binding of sialic acid, its natural substrate. 
Owning to the essential role of NA for release of progeny virions from the infected host 
cells, the inhibition of NA prevents virus spread and future replication in adjacent cells in 
the host. The mode of action of the NA inhibitor was proved by electron microscopy 
imaging (25). In the electron microscopy images, in the absence of inhibitor, separate 
rounded virions were observed on the surface of the cells; in the presence of oseltamivir 
carboxylate, clumped flattened virons were observed to attach to the cell surface, 
suggesting the failure to detach from the cell surface (25). As the neuraminidase active 
site is highly conserved in all types of influenza viruses, the NA inhibitors are effective 
against all human, avian and animal influenza viruses (25). The antiviral activity of the 
NA inhibitors have been demonstrated and proved in NA enzyme inhibition assays in 
vitro, infectivity reduction assays in cell culture, experimental animal models and human 
treatment experience (25;30). 
 
 
NA Inhibitor Resistance in Influenza A Viruses - Mechanism, Prevalence and 
Fitness 
 
The resistance to NA inhibitor can greatly reduce the therapeutic efficacy and 
disable the limited infection control options for influenza, so the susceptibility of the 
circulating influenza viruses to NA inhibitors have been closely monitored in clinical 
observation studies and surveillance studies. 
 
 Assessment of susceptibility of influenza viruses to NA inhibitors is primarily 
performed in functional NA inhibition assay in vitro and the NA genes of resistant 
viruses were further sequenced to understand the mechanism of resistance (38). The 
susceptibility of the virus to the drug can be firstly defined by the 50% percentage of 
inhibition concentration values (IC50) in NA inhibition assays. IC50 values vary by the 
type NA inhibition assay, influenza type and NA inhibitors tested, so the folds of change 
of IC50 values have been set as the criteria defining NA inhibitor resistance which is   
IC50 >10-fold means of the reference type/subtype sensitive influenza viruses to the 
drug (38). Thus, a significant increase of the IC50 value of a virus to a drug compared to 
the sensitive viruses can be defined as resistance or reduced susceptibility, although there 
is no clear-cut standard to differentiate both terms. Before the NA inhibitors were 
approved for clinical practice, over 1000 influenza virus isolates were examined for their 
susceptibility to NA inhibitors and they were found to be naturally sensitive (25).  
 
When influenza viruses resistant to NA inhibitors are identified, the resistance 
phenotype can be mapped to NA mutations by genotyping methods. The known 
resistance markers have been mapped to either the catalytic residues or framework 
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residues of NA active site. Apart from characterization of resistant virus genotype and 
phenotype, the impacts of resistance-associated mutations on the function of NA protein 
can be evaluated by enzyme kinetics, such as Km, Ki and Vmax etc parameters. Km is 
the dissociation constant for enzyme binding to the substrate, which is intrinsic to the 
enzyme and independent of the amount of protein presented in the reaction; Likewise, Ki 
is the dissociation constant for enzyme binding to the enzyme inhibitor; Vmax reflects 
catalytic capability of the enzyme active site and is dependent on both the enzyme 
turnover rate (Kcat) and the amount of enzyme presented in the reaction.  
 
After resistance genotype and phenotype of influenza viruses are characterized, 
the fitness of resistant viruses is of particular interest for further investigation. Viral 
fitness is defined as the degree of virus adaptation to a given environment or its relative 
ability to produce infectious progeny in a host (39). Originally, a growth competition 
experiment between different viruses is adopted to define the fitness degree of a virus 
relative to another virus (39) (40). However, due to the difficulty to quantitatively 
differentiate different genotypes in mixed populations, growth competitions cannot be 
always easily realized. As an alternative, now a comparative experiment using different 
viruses under the same experimental settings generally can be used to describe the fitness 
level of a virus relative to other viruses. The virus fitness can be evaluated in vitro or in 
vivo, such as virus growth kinetics and capability in different cell cultures, virus plaque 
morphology in cells and virus growth, pathogenicity and transmissibility in animal 
models etc infectivity parameters.  
 
In the follow sections, the mechanism and prevalence of the resistance to NA 
inhibitors in influenza A viruses is discussed, which includes human seasonal influenza A 
viruses, 2009 pandemic H1N1 viruses and emerging highly pathogenic H5N1 virus 
infection in human beings. The virus fitness of NA inhibitor-resistant viruses of different 
subtypes in comparison to their respective wild-type viruses in experimental models is 
also discussed, especially with a focus on the virus transmissibility, one of most clinical 
relevant properties of influenza A viruses. 
 
 
NA Inhibitor Resistance in Human Seasonal Influenza A Viruses 
 
Drug-selected resistance in human seasonal H1N1 and H3N2 influenza A 
viruses. After the NA inhibitors were approved for clinical use in 1999, the resistance to 
NA inhibitors emerged in clinical isolates during the NA inhibitor treatment in patients 
infected with seasonal H1N1 or H3N2 influenza viruses (41). The isolation of the 
resistant variants was associated with NA inhibitor treatment; as a result, they are referred 
as drug-selected resistance. In the clinical-derived resistant variants, NA inhibitor 
resistance associated mutations are found to be subtype-specific and drug-specific 
(32;42), either catalytic residues or the framework residues at the active site. It has been 
systematically summarized about the resistance-associated mutations found in the human 
seasonal influenza viruses of different type/subtype, and the susceptibility change to the 
three NA inhibitors caused by these mutations (32;42). With a focus on clinical isolates 
only, concisely, the catalytic residue R292K and framework residue E119V mutations 
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predominate in resistant H3N2 viruses; I222V mutation was reported occasionally in 
H3N2 viruses and N294S mutation was reported in one case of H3N2 virus infection, 
whereas the framework H274Y/H275Y (N2/N1 numbering; the actual numbering in the 
respective subtype were used afterwards) mutation is the most frequent resistance marker 
in H1N1 viruses. At the molecular function level, R292 is part of catalytic residues of 
enzyme active site responsible for binding to sialic acid and changing its conformational 
shape during reaction (43;44). The R292K mutation blocked the binding the NA 
inhibitors or sialic acid, consequently causing crossing-resistance to all three NA 
inhibitors. E119V mutations at the framework may permit a water molecule binding into 
the space of the residue Valine (V), which interfere with binding of oseltamivir but not 
zanamivir or sialic acid to the active site (45), therefore, E119V only results in resistance 
to oseltamivir, but not to the other two NA inhibitors. The H275Y mutation at the 
framework does not directly affect the enzyme catalytic sites, but it prevents the 
reorientation of E277 residue, which is required to accommodate oseltamivir to bind into 
the active site (43-45). Thus, the H275Y mutation only induces resistance to oseltamivir, 
not to other two NA inhibitors. It has been proposed that the R292K and N294S mutation 
may also prevent the reorientation of the E277 residue during the drug molecule    
binding (44;45).  
 
Serial passages of influenza A viruses in the presence of the NA inhibitors in cells 
or generation of reverse genetic viruses with the mutation at conservative amino acid 
residues in NA active site have created more NA inhibitors-resistant variants in vitro, 
with different levels of resistance to NA inhibitors (32;42). The resistance associated NA 
mutations identified in vitro is a growing list, which includes but is not limited to D151E, 
R152K, R371K, R118K, R224K, E227D, E276D, E119G/D/E etc mutations (N2 
numbering) (32;42). These mutations have not been found in the clinical isolates yet, 
perhaps due to their extremely reduced virus replication and infectivity, but they are of 
interest to understand the catalytic mechanism of NA active site and of implication for 
surveillance monitoring of NA inhibitor susceptibility.  
 
The detection rates of resistance from patients receiving NA inhibitor treatment in 
different clinical trials and clinical observation studies varied, depending on the treated 
subject and influenza virus type/subtype. For seasonal influenza A viruses, the incidence 
generally remained at low level till 2007. In early clinical trials of oseltamivir use for 
treatment of seasonal influenza, the emergence rate of resistance was about <1% in adults 
and 4~8% in children during the treatment, where the resistance was associated with 
H275Y mutation in H1N1 viruses, E119V and R292K mutation in H3N2 viruses (41;46). 
In later clinical observations, increased frequency of resistant variants detection (16% and 
27%) in drug-treated children was observed, and the resistance was also solely linked to 
the H275Y mutation in H1N1 viruses (41;47).  
 
The surveillance studies of NA inhibitors susceptibility of community isolates, 
which had no identified history of antiviral use in association with collection of the 
original clinical specimens, are informative to provide the prevalence of resistance in 
circulating viruses. Two early surveillance studies (46;48) conducted during the first 
three years of NA inhibitor use (2000~2003) tested thousands of influenza virus isolates 
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collected worldwide, and found no isolate or only 8 isolates resistant to oseltamivir 
respectively (0% or 0.33% resistance rate respectively), which suggesting extremely low 
prevalence of resistant viruses by then. More surveillance studies (32;49;50) conducted 
between 2003~2007 by different groups tested more influenza virus samples either 
collected globally or regionally from different countries including the ones of greatest 
oseltamivir use, constantly showed very low resistance rates (0.5%~1.7%) in 
characterized samples, suggesting that the very low prevalence of resistance in circulating 
viruses and no potentially transmissible resistance. However, the situation changed 
dramatically during the 2007-2009 season, when seasonal H1N1 viruses with common 
H275Y NA mutation were detected with high prevalence world widely under the context 
of absence of oseltamivir use (45). In differentiation with the drug-selected resistance 
above, this special phenomenon in the history of NA inhibitor resistance monitoring is 
referred as naturally occurring resistance and is further discussed in the section below. 
 
The virus fitness of NA inhibitor-resistant seasonal influenza viruses including 
infectivity and transmissibility compared with respective to wild-type viruses have been 
studied in experimental animal models (51-53). As regards to H1N1 viruses, in an earlier 
study, the H275Y mutant viruses exhibited severely compromised replication and 
virulence both in vitro and in ferrets compared to the wild-type viruses (54;55). The 
transmissibility of H275Y mutant viruses were firstly investigated in a ferret direct 
contact model, and the direct-contact transmission of a H275Y mutant of A/New 
Caledonia/20/99-like (H1N1) virus required a higher dose of inoculums than transmission 
of the wild-type viruses, and it occurred more slowly (53). Regarding to H3N2 viruses, 
an R292K mutant of A/Sydney/5/97-like H3N2 virus exhibited severely compromised 
infectivity and replication ability in ferret in comparison with the wild-type virus (55), 
and was not transmitted by direct contact among ferrets under the same conditions where 
the wild-type virus was transmitted (52). In a subsequent study, under similar conditions, 
an E119V NA mutant of A/Wuhan/359/95-like (H3N2) virus by ferret was transmitted by 
direct contact among ferrets but required a higher dose of inoculums than the wild-type 
virus, and the transmission occurred more slowly than the wild-type virus (53). In a 
different animal model, recombinant H3N2 influenza viruses carrying the E119V NA 
mutation or the double mutations E119V and I222V were transmitted efficiently among 
guinea pigs by direct contact but not by aerosol in comparison with the wild-type 
virus (51).  
 
These earlier studies differed in the virus subtypes studied (H1N1, H3N2), the NA 
mutations involved (H275Y, R292K, E119V or I222V), the animal model used (ferret or 
guinea pig), and the transmission routes studied (direct contact and respiratory droplets), 
but they commonly and consistently showed the virus fitness including infectivity and 
transmissibility of the NA inhibitor-resistant viruses carrying different NA mutations was 
lower sometimes even severely lower than the respective sensitive wild-type viruses, 
therefore, the NA inhibitor-resistant viruses were thought unlikely to be of clinical 
consequence. However, the later studies of virus fitness of the naturally resistant H1N1 
viruses showed very contrasting results, which were discussed in below section.  
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Naturally-occurring resistance in human seasonal H1N1 influenza A viruses. 
An exceptional phenomenon in the NA inhibitor resistance detection called 
naturally-occurring oseltamivir-resistance was observed in the seasonal H1N1 influenza 
viruses during two influenza seasons between 2008~ 2009 (45). During these seasons, the 
H1N1 influenza viruses with the common oseltamivir-resistance NA mutation H274Y 
(274 in N2 numbering, 275 in N1 numbering) were detected with high prevalence world 
wide under the context of absence of oseltamivir use (31;45;56). This particular 
phenomenon was a striking change compared with the situation during the years prior to 
2007, when the resistance incidence were usually connected with drug use and the 
detection rates were rather low. In differentiation with the drug-selected resistance, this 
special phenomenon is referred as naturally-occurring oseltamivir-resistance caused by 
the naturally resistant H1N1 viruses carrying the H275Y NA mutation in circulation.  
 
The naturally-occurring oseltamivir-resistance was firstly observed in Europe 
during the 2007-2008 season (57). In January 2008, Norway was the first to report high 
prevalence (68%) of resistant H1N1 viruses carrying the H275Y mutation in circulation 
(58). In early 2008, an average prevalence of resistant H1N1 viruses reached to 56% 
across the Europe (57). The resistant H1N1 viruses continue to spread to the southern 
hemisphere in following influenza season, such as Oceania, South Africa and South East 
Asia etc regions (59). By mid 2008, the southern hemisphere influenza season marked by 
a dramatic increase of the resistance rates from <1% to >90% in less than a year (59). In 
the following 2008~2009 influenza season, almost 100% of tested circulating H1N1 
viruses were resistant H275Y mutants in North America and other regions of the world 
(60). Clearly, the naturally resistant H1N1 variants were becoming the dominant 
circulating strains until the swine-origin pandemic 2009 H1N1 virus emerged. 
 
The rapid global surge of naturally resistant H1N1 viruses suggests that these 
H275Y mutant viruses owned higher virus fitness including transmissibility than their 
precedent wild-type viruses, although the previous epidemiologic and experimental data 
suggested otherwise. In view of this controversy, one study compared the effects of the 
H275Y mutation on the replication and virulence of old and recent influenza H1N1 
viruses (61). The results showed that the H275Y mutation caused impaired virus growth 
in cells only in the old A/WSN/33 virus but not in the recent A/Brisbane/59/07-like virus; 
the virulence of the recent A/Brisbane/59/07-like H275Y variant virus was not reduced in 
ferrets compared with the wild-type virus, consistent with its global dissemination.  
 
It has remained a puzzling question for a long time about the underlying 
mechanism of the optimal fitness of these naturally resistant H275Y mutant viruses, 
because the previous epidemiologic and experimental data suggested otherwise about 
fitness of the H275Y mutant H1N1 viruses. Surveillance studies provided informative 
clues for this question by examining the genetic changes in the H275Y mutant H1N1 
viruses. The phylogenetic analyses by different groups using various circulating H1N1 
viruses collected from respective regions showed two common features of these viruses 
(62-66). First, the NA and HA genes of seasonal H1N1 viruses exhibited same cluster 
patterns, which were classified as Clade 1, Clade 2A, 2B, 2C, represented by H1N1 
vaccine strains New Caledonia/20/1999 virus, Solomon Island/23/2006 virus, 
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Brisbane/59/2007 virus respectively (though no vaccine strain representing the 
Clade 2C); second, the vast majority of the naturally resistant viruses belonged to the 
Clade 2B in the phylogeny. Some studied further looked the genetic makeup of entire 
genome of the sensitive and resistant viruses and found that certain NA and HA amino 
acid substitutions and some intra-subtype reassortment events were associated with the 
naturally resistant viruses in phylogeny (65;66). These findings of genetic features in the 
naturally resistant viruses, especially their NA genes clustering together in the Clade 2B 
are enlightening to further understand their underlying molecular mechanisms. 
 
Two pioneering studies discovered different molecular phenotypes of the 
naturally resistant H1N1 viruses from different angles (67;68), and significantly 
advanced our understanding of the molecular mechanism of the naturally resistant H1N1 
viruses. The visionary work by M.A Rameix-Welti et al (68) , for the first time, revealed 
the distinct levels of NA enzyme affinity and distinct cluster patterns of the HA and NA 
genes among the old and newer isolates of seasonal H1N1 viruses. This study also 
showed that all the tested naturally resistant H275Y mutant viruses belonged to the high 
NA affinity group which genetically clustered together in the same group. This particular 
cluster was recognized as Clade 2B later and was consistently showed as a common 
feature for the naturally resistant H1N1 viruses characterized in different studies (62-66). 
Further studies have associated the high enzyme affinity in some viruses to certain NA 
amino acid substitutions (63;69) and one study confirmed the role of D344N substitution 
in increasing enzyme affinity (70). Another pioneering work by Bloom J. D et al (67), for 
the first time discovered that surface accumulation of a NA protein was reduced by the 
H275Y mutation and this defect could be counteracted by two permissive mutations 
Q222R and V234M which appeared prior to the H275Y mutation in the H1N1 virus 
evolution. This study is of significance to be the first to move the understanding of the 
effects of the H275Y mutation to protein expression level and firstly proposed the 
concept of “permissive” mutations for the H275Y mutation from the perspective of gene 
evolution. Following this findings, a recent study confirmed that the substitutions of the 
identified “permissive” residues into the “unpermissive” residues in the NA gene of a 
recent Clade2B virus compromised the corresponding H275Y mutant virus in vitro and in 
vivo (71).  
 
It remains an uncertain question where these naturally resistant H1N1 influenza 
viruses originated in the first place. As the H275Y NA mutation was not detected in 
influenza viruses in nature before the oseltamivir was approved for use at 1999, most 
likely, the progenitor H275Y mutant virus of the naturally resistant viruses still firstly 
emerged from the oseltamivir-treated patient under drug pressure, and the H275Y 
mutation was fixed into the ensuing virus population as a results of the identified 
permissive mutations and/or other unidentified mechanisms. The viruses carrying the 
H275Y mutation were further transmitted and spread, eventually becoming the naturally 
resistant H1N1 viruses. Another different and intriguing hypothesis about the origination 
of resistance is that the NA mutations at the enzyme active site could be a byproduct of 
HA protein avidity change resulted from immune escape of neutralizing antibodies (27). 
This study showed that HA immune escape of neutralizing antibodies resulted in NA 
antigenic variation and acquisition of NA mutations including H274N, V118I and 
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K253R, one of which altered the virus susceptibility to NA inhibitors. Although it 
remained uncertain what prompts the selection of those NA mutations, it provides an 
alternative view of the origination of the drug resistance. 
 
 
NA Inhibitor Resistance in 2009 Pandemic H1N1 Influenza A Viruses 
 
A novel swine-origin H1N1 influenza virus emerged in Mexico in April 2009 and 
rapidly spread worldwide, causing the first influenza pandemic of the 21st century. Most 
confirmed human cases of 2009 pandemic H1N1 virus (pH1N1) infection have been 
uncomplicated and mild, but the increasing number of cases and affected countries, and 
the sustained human-to-human transmission of the viruses, warranted optimal prevention 
and treatment measures. All tested the pH1N1 viruses carried resistant makers at M2 
gene to amantadine (72;73), so NA inhibitors especially oral oseltamivir were the first 
line of defense before the antigenically matched influenza vaccine became available. As a 
result, the oseltamivir use reached unprecedented volume during the 2009 pandemic. 
 
The scale and capability of monitoring of pH1N1 virus susceptibility to the NA 
inhibitor by global and national institutions was also unprecedented in the history (73). 
Since the detection of the pH1N1 viruses in April 2009, the first oseltamivir-resistant 
pH1N1 virus was reported at Denmark at as early as August 2009, which carried the 
common oseltamivir resistance marker NA H275Y mutation in N1 subtype and was 
isolated from a patient receiving oseltamivir prophylaxis (72;74). Subsequently during 
the pandemic, more sporadic oseltamivir-resistant variants have been isolated from 
individuals receiving prophylaxis, from immunocompromised patients receiving 
treatment, and from a few clusters of community isolates with no association to 
oseltamivir use (73;75-78). As of October 2011, among more than 600 reported 
oseltamivir-resistant variants (73), most of them are caused by the H275Y NA mutation, 
with a few exceptions linked to other NA mutations, which are introduced below. The 
low numbers of detected resistant variants indicate low prevalence of resistance in the 
circulating pH1N1 viruses so far. Different surveillance studies reported from 0% ~ 3% 
overall detection rate of resistant pH1N1 viruses varying from different periods and 
regions (73;79;80). However, the isolation of community transmitted resistant pH1N1 
viruses suggests that such viruses keep certain level of local transmissibility thus 
reinforces the need for continual surveillance.   
 
The pH1N1 viruses have the potential to become multi-NA inhibitor-resistant. In 
the clinical isolates of the pH1N1 viruses, apart from than the common H275Y mutation 
in the N1 subtype, several other NA mutations were firstly found in the N1 subtype of 
NA genes which induce different level of resistance to NA inhibitors (73;77;81;82). The 
NA I223R/I222R (N1/N2 numbering) mutation was identified in the clinical isolates of a 
patient receiving oseltamivir treatment, and this mutation alone can reduce the pH1N1 
virus susceptibility to all three NA inhibitors at a small degree (82). The I223R plus 
H275Y double mutations future enhanced the resistant level to oseltamivir. Another form 
of mutation I223V in the presence of H275Y mutation also has been identified in clinical 
isolates (77), which further enhanced the resistance to oseltamivir and peramivir, but did 
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not induced significant resistance to zanamivir (83) . The NA S247N mutation was 
founded at high frequency (10~30%) in several clusters of community isolates of pH1N1 
viruses (81). The S247N alone induced mildly reduced susceptibility to oseltamivir and 
zanamivir, not to peramivir, and the S247N plus H275Y double mutations significantly 
further enhanced the resistance level to oseltamivir, which have been found in clinical 
isolates (81).  
 
In view of the precedent example of the naturally resistant seasonal H1N1 viruses, 
understanding the virus fitness of H275Y mutant resistant pH1N1 viruses in laboratory 
based experiments were of special urgency under the pandemic context. Diverse isolates 
of H275Y mutant pH1N1 viruses were subjected to extensive characterization and 
assessment of infectivity and transmissibility in different animal models by individual 
groups (84-88). The results across different studies reached some agreement on certain 
conclusion that the H275Y mutant pH1N1 viruses had replication capability, 
direct-contact transmissibility and overall virulence in animals similar or equivalent to 
those of the wild-type viruses. However, these studies showed the biggest variation on 
the transmissibility by respiratory droplet or aerosol route. Compared with their 
respective wild-type viruses, two studies showed greatly reduced respiratory-droplet 
transmissibility of two different H275Y resistant pH1N1 isolates in ferrets (84;86); one 
study exhibited delayed respiratory-droplet transmissibility in one tested pH1N1 isolates 
but essentially the same transmissibility in another isolate in ferrets (87); one study 
observed the equivalent respiratory-droplet transmissibility of two reverse-genetics 
derived H275Y mutant pH1N1 viruses in both ferrets and guinea pigs (88). Nevertheless, 
these different results might be partly due to the various sources of pH1N1 viruses with 
subtle different genetic backgrounds and different experimental settings. The fact that the 
oseltamivir-resistant H1N1/2009 viruses remained certain level of transmissibility 
underlines the necessity of continuous monitoring of drug resistance of circulating 
pH1N1 viruses. 
 
The clinical-derived NA inhibitor resistant pH1N1 viruses carrying the new 
resistance mutations also raised the concern about their virus fitness. Some of the 
resistant variants have been assessed for their fitness especially transmissibility relative to 
wild-type viruses in experiments. Regarding to NA 223 mutation, one study showed that 
an I223R mutant virus isolate has comparable replication ability and transmissibility but 
lower pathogenicity in ferrets than the wild-type virus (89). Another study observed that 
the virus infectivity and transmissibility in ferrets were comparable among the wild-type, 
the H275Y only mutant and the I223V plus H275Y mutant pH1N1 viruses generated by 
reverse genetics techniques (90). As regards to the NA S247N mutation, in a study using 
reverse-genetics pH1N1 viruses in guinea pigs (91), the S247N mutation only virus 
showed reduced respiratory-droplet transmissibility and the S247N plus H275Y double 
mutation exhibited even further reduced transmissibility compared to the wild-type virus, 
however, when the reverse-genetics pH1N1 virus were rescued from another NA genetic 
background of pH1N1 virus, the S247N mutation only and S247N plus H275Y double 
mutations caused the same reduced transmissibility compared to the wild-type virus. 
These results suggest that the diverse NA genetic background can cause variation of the 
virus fitness especially with the presence of the resistance-associated NA mutations. 
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NA Inhibitor Resistance in Human Infection of Highly Pathogenic H5N1 Influenza 
A Viruses 
 
Highly pathogenic avian H5N1 viruses have special clinical relevance to human 
beings. Since the first human cases in 1997 in Hong Kong (92), sporadic human infection 
with highly pathogenic avian H5N1 influenza virus has been reported across Asia, 
Europe, Africa and the Middle East (9). Human infection of highly pathogenic H5N1 
virus exhibited severe pneumonia or acute respiratory distress syndrome with a mortality 
rate higher than 60% (9;93). In view of that seasonal influenza vaccine does not have 
effective cross reactivity again the H5N1 influenza viruses, the antiviral drugs especially 
NA inhibitors are standing at the first line of defense of the H5N1 virus infection.  
 
The NA inhibitor resistance in H5N1 viruses is a serious concern for public 
health, thus the susceptibility of H5N1 virus has been evaluated and human infection of 
H5N1 has been closely monitored. Phenotypic resistance test using H5N1 viruses from 
south-east Asia showed that the viruses were generally sensitive to NA inhibitors but 
with variability, depending on virus clades and isolation time (9;25). In human infection 
of highly pathogenic H5N1 viruses, oseltamivir-resistant variants have been isolated from 
patients receiving oseltamivir treatment or prophylaxis and resistance were associated 
with two mutations H275Y or N294S at NA framework (9;94). Likewise in human N1 
subtype viruses, the H275Y NA mutation in H5N1 viruses induced resistance to 
oseltamivir and reduced susceptibility to peramivir but not to zanamiivir. The N294S NA 
mutation was identified in one case of H3N2 human influenza virus previously (41), and 
was only found in clinical isolates of H5N1viruses of N1 subtype so far (9;95), which 
induced moderate resistance to oseltamivir. By far, the H275Y vairant were isolated from 
3 cases during the N294S variant were isolated from 2 cases in Egypt (9;96;97). One 
highly pathogenic H5N1 virus isolated from a patient treated with oseltamivir had a 
mixed oseltamivir-sensitive and -resistant population, and the later were identified as 
either H274Y or N294S NA mutations by plaque purification (97).  
 
The infection of highly pathogenic H5N1 viruses in animal models exhibited 
some special features different from human seasonal influenza viruses, such as extremely 
high viral loads, systematic spread nature etc, high lethality etc (98). Especially, the 
highly pathogenic H5N1 viruses can effectively infect mouse and cause lethality without 
the need of prior adaptation like the human seasonal influenza viruses, making the mouse 
model for useful evaluation of the virus fitness of H5N1 viruses. In both mouse and ferret 
model, the reverse-genetics variants of a highly virulent strain A/Vietnam/1203/04 H5N1 
virus carrying either the H275Y or N294S NA mutation retained their replication 
efficiency and pathogenicity in vitro and in vivo similar to the wild-type H5N1 virus (99). 
Also tested in both mouse and ferret models, the clinical-derived variants of 
A/Hanoi/30408/2005 H5N1 virus carrying either the H275Y or N294S NA mutation 
were attenuated in terms of pathogencity compared to the wild-type virus, with a bigger 
degree of attenuation in the H275Y mutant than in the N294S mutant (97;100).  It is 
worth to note that both the H5N1 viruses both belong to HA clade 1 of H5N1 virus 
phylogeny, but A/Hanoi/30408/2005 overall was less virulent than the 
A/Vietnam/1203/04 virus in tested animal models (99;100). In a virus growth compitition 
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experiment for direct comparasion of virus fitness in ferrets (101), as for a clade 2.2 
H5N1 virus, the virus fitness of reverse-gnetics H275Y mutant of A/Turkey/15/2006-like 
H5N1 virus was less than the wild-type virus, but regarding to a clade 1 H5N1 virus, the 
virus fitness of the reverse-genetics H275Y mutant of A/Vietnam/1203/04 H5N1 virus 
was equivalent to the wild-type virus, suggesting the virus fitness change of the resistant 
H5N1 viruses were associated with the virus genetic background, other than the 
resistance markers. 
 
 
Concluding Remarks 
 
The development of NA inhibitor resistance is a huge drawback to the control of 
influenza infection by antiviral drugs. The experimental studies of the NA 
inhibitor-resistant influenza viruses of different type/subtypes have significantly 
advanced our understanding of the molecular mechanism of the resistance, change of 
virus fitness in the resistant viruses. These studies have exerted significant implications 
on surveillance monitoring of susceptibility of circulating influenza viruses to NA 
inhibitors. On the other hand, some different studies of fitness of the resistant virus of a 
same resistance marker reached disparate conclusions towards their clinical relevance. 
The reasons for such discrepancy could be simply from the virus variants used, or the 
different animal models tested or the diverse experiment setting used. The different 
genetic backgrounds of the viruses could be subtle difference in NA gene contexts such 
as in the naturally resistant H1N1 viruses vs the drug-induced resistant H1N1 viruses, or 
could be in the genome such as in the highly pathogenic H5N1 viruses of different clades. 
The further advancement of understanding molecular mechanism of fitness of NA 
inhibitor-resistant viruses necessitates combination of multiple parameters at different 
levels from viral genes to viral proteins to viruses. The risk of emergence of NA 
inhibitor-resistant influenza viruses with undiminished fitness should be an alert for 
surveillance monitoring and experimental studies of circulating influenza viruses. 
 
 Overall, NA proteins play an essential role in influenza A virus infection in hosts, 
and the use of NA inhibitors for treatment of influenza virus infection has induced 
resistant viruses with different NA mutations. Consequently, how the resistance 
associated mutations affect NA function and fitness of the mutant influenza viruses 
remain a big question and are subject for further investigation. In the following two 
chapters, two studies investigated the impacts of an oseltamivir resistance-associated 
mutation (NA H275Y) in the 2009 pandemic H1N1 virus or the seasonal H1N1 virus 
background on the virus in vitro and in vivo fitness including transmissibility. These 
studies aim to evaluate and understand resistant-virus fitness by integrating multiple 
parameters at different levels from genes to proteins to viruses. The related backgrounds, 
specific questions and aims of each study are introduced separated in each chapter. 
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CHAPTER 2.    THE VIRUS FITNESS AND TRANSMISSIBLITY OF AN 
OSELTAMIVIR-RESISTANT 2009 PANDEMIC H1N1 INFLUENZA A 
VIRUS* 
 
 
Introduction 
 
A novel swine-origin H1N1 influenza virus emerged in Mexico in April 2009 and 
rapidly spread worldwide, causing the first influenza pandemic of the 21st century (6;7). 
Most confirmed human cases of H1N1/2009 influenza have been uncomplicated and mild 
(102), but the increasing number of cases and affected countries warrant optimal 
prevention and treatment measures. At present, two classes of antiviral drugs are 
approved for specific management of influenza: M2-ion channel blockers (amantadine 
and rimantadine) and neuraminidase (NA) inhibitors (zanamivir and oseltamivir). 
However, variants resistant to both classes of drugs have emerged. During the 2007-2008 
season, most circulating seasonal H3N2 influenza viruses, and H1N1 viruses in certain 
geographic areas, were reportedly resistant to M2-blockers (103;104); today, almost all of 
the pandemic H1N1/2009 viruses tested are resistant to M2-blockers (72). Therefore, 
only the NA inhibitors are currently recommended for treatment of influenza (105). 
 
The NA-inhibitor resistance-associated mutations in influenza viruses are 
drug-specific and NA subtype-specific (106). Until 2007, the clinical data indicated only 
sporadic, rare emergence of oseltamivir resistance under drug selection pressure (< 1% in 
adults and 4%-8% in children) (41;107;108). Later reports observed increased frequency 
of oseltamivir-resistant variants (16 % and 27%) in drug-treated children (47;108). The 
situation changed dramatically during the 2007-2008 season, when seasonal H1N1 
influenza viruses with the common oseltamivir-resistance NA H275Y mutation (275 in 
N1 numbering, 274 in N2 numbering) became widespread in first the northern (109) and 
then the southern (59) hemispheres. It remains uncertain where these naturally resistant 
H1N1 influenza viruses originated and how they acquired optimal fitness and 
transmissibility, but the resistant variants were clearly becoming the dominant strain at 
the time the swine-origin pandemic H1N1/2009 virus emerged (45;56;60). During the 
H1N1/2009 influenza pandemic, to date, almost all tested viruses have remained 
susceptible to oseltamivir and zanamivir (72), but oseltamivir-resistant variants with 
H275Y NA mutation have been isolated from individuals receiving prophylaxis (77;110) 
and from immunocompromised patients (76) under drug selection pressure. 
Oseltamivir-resistant variants also have been isolated from untreated patients (111;112) 
and from a few community clusters (75;113;114), including two suspected cases of 
nosocomial transmission among immunocompromised patients (75;114), although it is 
uncertain whether the mutants came from secondary transmission or arose spontaneously. 
The  
 
* Chapter 2 adapted with permission. Duan,S., Boltz,D.A., Seiler,P., Li,J., Bragstad,K., 
Nielsen,L.P., Webby,R.J., Webster,R.G., and Govorkova,E.A. 2010. 
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower 
transmissibility and fitness in ferrets. PLoS. Pathog. 6:e1001022.  
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isolation of resistant H1N1/2009 viruses with no link to oseltamivir use raised serious 
concern that these viruses might acquire fitness and spread worldwide, as had 
oseltamivir-resistant seasonal H1N1 viruses during 2007-2008 season. 
 
The increasing concern about oseltamivir-resistant H1N1/2009 viruses prompted 
us to evaluate transmissibility and growth fitness of one oseltamivir-resistant variant. The 
infectivity and transmissibility (and thus the clinical relevance) of several NA 
inhibitor-resistant influenza viruses have previously been studied in experimental animal 
models (51;52;115;116). These studies differed in the influenza A subtypes studied 
(H1N1, H3N2, or H5N1), the NA mutations involved (H275Y, R292K, E119V or 
I222V), the animal model used (ferret or guinea pig), and the transmission routes studied 
(direct contact and respiratory droplets); in these studies, the transmissibility of most of 
the NA inhibitor-resistant influenza viruses was to some extent less efficient. Here we 
characterized in vitro and in a ferret model a pair of pandemic H1N1/2009 clinical 
isolates. The pandemic A/Denmark/524/09 (A/DM/524/09) and A/Denmark/528/09 
(A/DM/528/09) viruses were isolated from a small cluster of patients with H1N1/2009 
virus infection. The A/DM/528/09 virus, carrying the H275Y NA mutation, was isolated 
from a patient on oseltamivir prophylaxis, and its ancestor is likely to have been 
A/DM/524/09 virus. By recapitulating two natural routes of influenza virus transmission 
in ferrets, we found that the oseltamivir-resistant virus was less transmissible than its 
sensitive counterpart through the respiratory droplet route but retained efficient 
transmission through direct contact.  
 
 
Results 
 
 
Sequencing and Phylogenetic Analysis of NA Genes 
 
Sequence analysis of the NA genes revealed that A/DM/524/09 virus encoded a 
conserved H residue at amino acid position 275, whereas A/DM/528/09 virus had an 
H275Y amino acid mutation caused by a single T-to-C nucleotide substitution at codon 
275 (Table 2-1). Pairwise sequence analysis of the full viral genomes showed that the 
A/DM/524/09 and A/DM/528/09 viruses had no amino acid differences other than the 
H275Y NA mutation and were a highly matched pair. Sequence analysis and 
phylogenetic analysis of the two viruses NA and HA genes (data not shown) confirmed 
that the wild-type A/DM/524/09 and mutant A/DM/528/09 viruses belonged to the 
swine-origin 2009 pandemic virus lineage. The alignment of the NA and HA sequences 
showed that viruses with H275Y NA substitution have some amino acid differences from 
certain wild-type viruses (without H275Y NA mutation), but these differences also were 
observed in other wild-type viruses. Comparison of the NA and HA amino acid 
sequences of A/DM/528/09 virus with sequences of other 24 H275Y mutants and around 
2000 wild-type H1N1/2009 viruses available in Gene Bank did not reveal an increased 
frequency of any specific amino acid mutation(s) shared among the viruses analyzed 
(data not shown). 
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Table 2-1. Neuraminidase enzymatic properties of the H1N1 influenza viruses. 
 
H1N1 viruses 
Sequence at NA  
position 275  
NA enzyme inhibition     
IC50 ±SDa (nM) 
Enzyme kineticsb 
Nucleotide Amino acid  Oseltamivir carboxylate Zanamivir Km (μM)
Vmax 
(U/sec) 
Pair 1 (pandemic)        
A/Denmark/524/09 CAC H  5.0±0.8 1.3±0.15 55.1±4.2 101.6±7.9 
A/Denmark/528/09 TAC Y  972±283* 1.0±0.13 80.3±6.0* 86.8±5.6* 
Pair 2 (seasonal)        
A/Brisbane/59/07 CAT H  6.2±0.6 1.0±0.1 23.7±1.7 66.5±11.2 
  A/New Jersey/15/07 TAT Y  1546±327* 1.4±0.1 35.0±2.8* 37.4±13.5*
 
a The full genomes of both viruses were sequenced; only differences are shown. In order of segments, the GenBank accession 
numbers are CY043339 - CY043346 for A/DM/524/09 virus and CY043347 - CY043354 for A/DM/528/09 virus genome 
sequences. 
b Mean ± SD from five independent measurements. Assayed in parallel with reference A/Fukui/08/02 (H3N2) virus. Km and 
Vmax values were derived from the Michaelis-Menten plot. 
* P<0.05 compared to value for respective wild-type virus.
 21 
NA Inhibitor Susceptibility and NA Enzyme Kinetics  
 
 To assess the NA inhibitor susceptibility of the two viruses, we performed NA 
enzyme inhibition assays with the NA inhibitors oseltamivir carboxylate (active 
metabolite of oseltamivir) and zanamivir. The wild-type A/DM/524/09 virus was 
susceptible to oseltamivir carboxylate (mean IC50: 5.0 nM), but the A/DM/528/09 
carrying the H275Y NA mutation had IC50 values approximately 200 times that of the 
wild-type virus (Table 2-1). The IC50 of zanamivir was comparable for both viruses and 
was uniformly low (mean IC50 ? 1.3 nM) (Table 2-1). These results showed that the 
H275Y NA mutation conferred resistance to oseltamivir carboxylate but did not alter 
susceptibility to zanamivir.  
 
 To understand the impact of the H275Y mutation on the NA enzymatic properties 
of the H1N1/2009 viruses, we determined the NA enzyme kinetics of both viruses. Km is 
an estimate of the dissociation equilibrium for substrate binding to enzyme and the 
reciprocal of Km approximates the affinity of substrate binding, while Vmax reflects the 
enzyme’s catalytic activity. The NA of resistant A/DM/528/09 virus had a slightly higher 
Km and lower Vmax than the NA of the sensitive A/DM/524/09 virus (Table 2-1). The 
H275Y NA mutation reduced NA affinity for substrate and NA catalytic activity, 
although the function of NA was not severely impaired. This finding in the H1N1 
pandemic virus is similar to that reported by another group, in which NA enzymatic 
function was not impaired in some naturally resistant seasonal viruses isolated during the 
2007 season (117). Our study is the first to show reduced but not severely impaired NA 
enzymatic function in a resistant H1N1/2009 virus with the H275Y mutation. 
 
 
Plaque Morphology and Growth Kinetics in Cells 
 
To determine whether the H275Y NA mutation affects virus growth in vitro, we 
characterized virus plaque morphology and growth kinetics in both MDCK and 
MDCK-SIAT1 cells. The latter have increased surface expression of human-like 
?2,6-linked terminal sialic acids (118) and may better assess the growth capability of 
human influenza viruses. In MDCK cells, both pandemic H1N1/2009 viruses formed 
pinpoint-like (0.3 mm) plaque phenotype (Fig 2-1A), differing significantly from some 
seasonal H1N1 viruses, such as A/Brisbane/59/2007 (BR/59/07) virus, which formed 
large plaques (1.3 mm) (P<0.05) (data not shown); however, the plaque size did not differ 
between the oseltamivir-sensitive and -resistant viruses (Fig 2-1A), indicating that the 
H275Y NA mutation did not alter plaque morphology. In MDCK-SIAT1 cells, both the 
pandemic viruses and seasonal BR/59/07 (data not shown) formed only pinpoint-like 
plaques (Fig 2-1B), consistent with a previous report (118) that this cell line did not 
generate clear plaques for influenza viruses. 
 
To further evaluate the impact of the H275Y NA mutation on virus growth in 
vitro, we performed single- and multiple-cycle growth studies of both viruses in MDCK 
and MDCK-SIAT1 cells. In single-cycle growth in the two cell lines, the two viruses 
reached comparable levels 6 hours post-infection, but the initial growth of the 
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Figure 2-1. Plaque morphology and replication kinetics of two H1N1/2009 influenza 
viruses in MDCK and MDCK-SIAT1 cells. 
 
The diameters of 20 randomly selected value plaques were measured in MDCK cells (A) 
and MDCK-SIAT1 cells (B). Values are mean (± SD) plaque diameter (mm). 
Single-cycle (C, D left panel) and multiple-cycle (C, D right panel) growth curves were 
obtained by using an MOI of ~2 and ~0.001 PFU/cell, respectively. Virus in the 
supernatant was titrated in MDCK or MDCK-SIAT1 cells and expressed as 
log10TCID50/ml at the indicated time post-infection. Each point represents the mean 
log10TCID50/ml ± SD from three experiments. * P<0.05 compared to value for wild-type 
viruses.
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oseltamivir-resistant virus was significantly delayed in comparison to its sensitive 
counterpart (P<0.05) (Fig 2-1C): at 4 hours post-infection, the yield of resistant viruses 
was at least 1 log10TCID50/ml lower (P<0.05). Likewise, in multiple-cycle growth, the 
two viruses reached comparable yields 24 hours post-infection, but the resistant virus 
showed a significant growth delay during the first 12 hours post-infection (P<0.05); this 
delay was more conspicuous in MDCK-SIAT1 cells than in MDCK cells (Fig 2-1D), 
probably because overexpressed ?2,6 receptors on cell surface could better differentiate 
NA’s function in support of viral growth. Therefore, final virus yields of 
oseltamivir-resistant pandemic virus in the MDCK and MDCK-SIAT1 cells were not 
altered, but their growth at the initial infection stage was significantly delayed. 
 
 
Transmissibility among Ferrets via Direct-contact and Respiratory-droplets Routes 
 
The transmissibility of pandemic H1N1/2009 viruses was studied in a ferret 
model. Two naïve ferrets were housed at day 2 post-inoculation (p.i.) in the same cage 
with one inoculated ferret (direct contact), and two naïve ferrets were placed in an 
adjacent cage separated from the donor’s cage by two layers of wire mesh (respiratory 
droplet exposure). Transmission of H1N1 virus was assessed by detection of infection in 
recipient ferrets (nasal wash titers, clinical signs, and seroconversion). Virus samples in 
nasal washes at day 4 p.i. or post-contact (p.c.) were sequenced to detect the presence of 
the H275Y NA mutation. 
 
The donor ferret inoculated with oseltamivir-sensitive A/DM/524/09 virus shed 
virus until day 6 p.i. (Fig 2-2A, Table 2-2). Two of 2 direct-contact ferrets and 1 of 2 
respiratory droplet-exposed ferrets were infected through virus transmission, as indicated 
by the virus titers and inflammatory cell counts in their nasal washes (Fig 2-2) and by 
seroconversion (Table 2-3). Virus shedding and nasal inflammation began earlier in the 
direct-contact ferrets, suggesting that transmission through respiratory-droplets may have 
a greater lag time. One respiratory droplet-exposed ferret showed no detectable virus 
shedding or inflammation, but its post-contact serum had a positive HI titer (320). 
Although seroconversion indicated infection in this ferret, the time of infection could not 
be determined and therefore we could not attribute the infection to direct contact with the 
co-caged ferret versus respiratory droplet transmission from the adjacent cage. 
 
The donor ferret inoculated with oseltamivir-resistant A/DM/528/09 virus shed 
virus until day 8 p.i. (Fig 2-2), with a peak virus titer comparable to that of A/DM/524/09 
virus (Table 2-2). Two of 2 direct-contact ferrets were infected through transmission (Fig 
2-2), but neither respiratory droplet-exposed ferret was infected, as confirmed by the 
absence of seroconversion (Table 2-3). These results showed that the resistant H275Y 
mutant A/DM/528/09 virus was transmitted efficiently only by direct contact. Virus 
shedding in two direct-contact ferrets was lower and peaked after a longer interval in this 
group than in the oseltamivir-sensitive A/DM/524/09 group (Fig 2-2A), although the 
severity and course of disease were similar (Fig 2-2B, Table 2-3).  
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Figure 2-2. Transmissibility of the two H1N1/2009 influenza viruses among ferrets. 
 
The virus titer (A, B left panel) and total number of inflammatory cells (A, B right panel) 
in the nasal wash samples from each donor ferret, direct-contact (DC contact) ferret, and 
respiratory droplet-contact (RD contact ) ferret. The arrow indicates the first day of 
exposure of contact ferrets. 
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Table 2-2. Clinical signs, virus replication and sero-conversion in inoculated donor ferrets. 
 
 H1N1 virus 
Inoculated donor ferretsa 
Clinical signs  Virus replication 
Weight 
lossb (%) 
Sneezing
(day of 
onset) 
Last day  
of 
inflammationc
 
Peak virus 
titer 
(day p.i)d 
Last day 
of 
sheddinge
Serum 
HI titerf 
 A/Denmark/524/09 5.0 (2) 3 12  7.3 (2) 6 1280 
 A/Denmark/528/09 6.2 (2) 7 12  6.9 (2) 8 640 
 Co-inoculationg  5.9 (4) 7 12  7.7 (2) 6 640 
 
a n=1 for each virus group. 
b The maximum percent weight loss during the 21 days p.i. Numbers in parentheses indicate the day of maximum weight loss.  
c Upper respiratory tract inflammation was defined as a total inflammatory cell count ? 10 times the baseline count. 
d Virus titers in nasal washes (log10TCID50/ml).   
e The first day of observation on which virus was not detected. 
f Hemagglutination inhibition (HI) antibody titers to homologous virus 21 days p.i. 
g Co-inoculation of ferret with A/DM/524/09 and A/DM/528/09 viruses at 1:1 ratio.
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Table 2-3. Clinical signs, virus replication, and seroconversion in contact ferrets. 
 
H1N1 virus 
Direct contact  
 
        Respiratory droplets 
Clinical signs  Virus detection Clinical signs  Virus detection 
Weight 
lossa  Sneezing
b  Virus sheddingc
Last day 
of 
sheddingd 
 Serum 
HI  
titere 
Weight  
lossa Sneezing
b  Virus 
sheddingc
Last day  
of  
sheddingd
 Serum  
HI 
   titere 
A/Denmark/524/09 2/2 (3.5) 
1/2 
(7) 
 
 
2/2 
(8.3) 8, 8 
1280, 
640 
 
    1/2 
(6.0) 
1/2 
(7) 
 
 
1/2 
(7.2) 10 
1280, 
320 
A/Denmark/528/09 2/2 (3.3) 2/2 (5,7) 
 
 
2/2 
(7.0) 8, 10 
1280, 
    1280   0/2 0/2  0/2 NA 
<10, 
<10 
Co-inoculation f 2/2 (6.0) 
1/2 
(2) 
 
 
2/2 
(7.1) 10, 10 
1280, 
    1280   NA NA  NA NA NA 
 
a Number of animals with weight change/total number (maximum percent weight loss during the 21 days p.c.).  
b Number of animals sneezing/total number during the 21 days p.c. (day of observed onset). 
c Number of virus-shedding animals/total number. Numbers in parentheses indicate mean peak virus titer (log10TCID50/ml) in  
  nasal wash samples).   
d The first day of observation on which virus was not detected. 
e Hemagglutination inhibition (HI) antibody titers to homologous virus in ferret serum on day 21 p.c. 
f Donor ferret was co-inoculated with A/DM/524/09 and A/DM/528/09 viruses at a 1:1 ratio.
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We verified the sequence stability of the NA at position 275 in each virus after 
replication and transmission in ferrets. Direct sequencing of the NA genes from nasal 
wash samples revealed no sequence change at this position in either virus (data not 
shown). Therefore, no spontaneous H275Y NA mutation emerged in the wild-type virus 
and the H275Y mutation remained stable in the mutants after transmission to a new host. 
 
 
Co-inoculation with Oseltamivir-sensitive and -resistant H1N1/2009 Viruses 
 
 Because both the oseltamivir-sensitive and the oseltamivir-resistant H1N1/2009 
viruses were efficiently transmitted by direct contact, hosts could potentially be exposed 
to both types of virus. To compare the relative growth capability and transmissibility of 
the sensitive and resistant H1N1/2009 viruses within the host, we co-inoculated a ferret 
with a 1:1 ratio of the sensitive A/DM/524/09 and resistant A/DM/528/09 viruses. The 
pattern of virus shedding and the clinical signs were similar to those in ferrets inoculated 
with either A/DM/524/09 or A/DM/528/09 virus (Fig 2-3A). By using a relative 
quantification of single nucleotide polymorphism (SNP) method to detect the NA 
genotype at codon 275 (CAC or TAC), we found that the virus population in the 
co-inoculated ferret’s nasal washes remained mixed but was predominantly a wild-type 
(oseltamivir-sensitive) population (Fig 2-3B). The proportion of wild-type virus in the 
nasal wash increased progressively, from 75% on day 1 p.i., to almost 100% on day 6 p.i. 
(Fig 2-3B). Two of 2 ferrets placed in direct contact with the co-inoculated ferret were 
infected through transmission (Fig 2-3A). SNP analysis of their nasal wash samples 
showed only wild-type virus (Fig 2-3B). In summary, the oseltamivir-sensitive 
A/DM/524/09 virus possessed greater growth capability in the upper respiratory tract 
than did resistant A/DM/528/09 virus and thus had an advantage in direct-contact 
transmission. 
 
 
Discussion 
 
This study is the first, to our knowledge, to demonstrate the inefficient respiratory 
droplet transmission of an oseltamivir-resistant H275Y mutant of H1N1/2009 in ferrets, 
which are an established animal model of the pathogenesis and transmission of human 
influenza viruses. The oseltamivir-resistant mutant virus retained efficient transmission 
only by direct contact, whereas the oseltamivir-sensitive pandemic virus was efficiently 
transmitted by both routes. These results show that the transmissibility of the 
oseltamivir-resistant H1N1/2009 influenza virus had been altered. We suggest that the 
lower fitness of oseltamivir-resistant variant within the host along with its reduced NA 
enzyme efficiency and delayed growth of the H275Y mutant virus in vitro may at least in 
part explain its impaired transmission among ferrets. 
 
There are limited experimental data about the routes of transmission of 
oseltamivir-resistant influenza viruses. The two natural routes of influenza virus 
transmission, direct contact with fomites and respiratory droplets (aerosol and larger 
droplets (119), are not mutually exclusive. Therefore, the transmissibility of influenza 
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Figure 2-3. Co-infection with oseltamivir-sensitive and -resistant H1N1/2009 
influenza viruses.  
 
Virus titers and inflammatory cell counts in the nasal wash specimens of ferrets 
co-inoculated with oseltamivir-sensitive and -resistant H1N1/2009 viruses (A). The arrow 
indicates the first day of exposure of contact ferrets. The proportion of wild-type virus (C 
in SNP sequence) in the mixed virus population (C+T in SNP sequence) in nasal wash 
samples from the donor ferret and two direct-contact ferrets (B). Values are the mean ± 
SD from three independent measurements. * P<0.05 compared to value for day 0 p.i. 
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viruses via both routes must be investigated if the results are to be clinically relevant. In 
the earliest studies, oseltamivir-resistant H3N2 (R292K NA mutant) and H1N1 (H275Y 
NA mutant) variants exhibited severely compromised replication and virulence both in 
vitro and in vivo (54;55) and were therefore thought unlikely to be of clinical 
consequence. In a subsequent study, an R292K mutant of H3N2 virus was not transmitted 
by direct contact among ferrets (52). Under similar conditions, the transmission of an 
E119V mutant of H3N2 virus and an H275Y mutant of A/New Caledonia/20/99-like 
H1N1 virus by direct contact required a higher dose of inoculum than transmission of the 
wild-type viruses, and it occurred more slowly (120). However, none of these studies 
assessed both routes of transmission. The only study to date that has evaluated both 
routes of transmission of oseltamivir-resistant virus showed that recombinant resistant 
H3N2 viruses with either the E119V or the E119V+I222V NA mutation were transmitted 
efficiently by direct contact but not by respiratory droplets among guinea pigs (51). Our 
study is a latest addition to the previous data by comparing a highly matched pair of 
H1N1/2009 viruses and by assessing the transmissibility of resistant viruses via two 
routes in ferrets.  
 
The reduced transmissibility of the oseltamivir-resistant H1N1 viruses could be 
explained by a number of factors (121-123). First, host physical exposure to virus is 
directly affected by the quantity of virus shed into the environment. In our study, 
inoculated donor ferrets shed comparable quantities of both viruses, which indicated 
potential comparable environmental contamination in the restricted space of cages; 
therefore, it is unlikely that transmission was affected by the level of donor viral 
shedding. Other host variables such as the extent of inflammation could affect the amount 
and size of upper respiratory secretions thus the release of infectious respiratory droplets. 
For example, sneezing, a common host symptom believed to mediate viral transmission, 
was observed only at later stages in the ferret inoculated with resistant virus, when 
inflammation was more severe but virus shedding had declined greatly. Second, efficient 
transmission to a naive host requires not only viral exposure but also successful viral 
invasion, effective replication and simultaneous evasion of the first line of host innate 
immunity (124). Our results showed a significant initial growth delay in two cell lines of 
the resistant virus. This growth delay could be caused by delayed release of progeny 
virions from the host cell surface due to reduced NA enzyme efficiency observed in the 
resistant virus. Such a delay would not affect the final virus yield in cell lines, but in the 
respiratory tract of ferrets it could allow the host’s first-line innate immune defense (e.g., 
macrophages or neutrophils) sufficient time to clear the virus. The NA enzyme also 
facilitates virus binding, entry, and spread within the host by removing terminal 
sialic-acid residues from mucus and preventing virion self-aggregation (25), and 
therefore the NA mutation could have affected viral penetration into the host respiratory 
tract. The slightly reduced (not severely impaired) NA enzyme function and delayed viral 
growth of the H275Y mutant may have been more crucial in recipient ferrets that 
acquired virus from environment via natural routes than in donor ferrets inoculated with a 
high dose of virus, as we observed delayed viral shedding or inefficient transmission in 
the recipient ferrets, but not in the inoculated donor ferret. 
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Although the transmissibility of the oseltamivir-resistant H1N1/2009 virus was 
reduced by the H275Y NA mutation, the severity and course of disease was similar to 
that caused by oseltamivir-sensitive H1N1/2009 virus in both inoculated and 
direct-contact ferrets, with no apparent attenuation of clinical signs. In inoculated ferrets, 
the viruses showed comparable replication in the upper respiratory tract and caused 
comparable clinical signs, including weight loss and inflammation. However, one caveat 
to ferret model has been noticed that high inoculation dose may mask the differential 
viral replication and clinical signs for different viruses (125). In the direct-contact ferrets, 
which acquired virus though natural routes, the shedding of resistant virus peaked later 
than the shedding of susceptible virus, but the duration of shedding and the severity of 
disease was not compromised when compared with sensitive virus. Therefore, the H275Y 
mutant of pandemic H1N1/2009 virus is likely to be of clinical consequence in humans.  
 
The fitness of a virus describes its relative ability to produce infectious progeny in 
a host (39).  Competitive growth assay by co-infection is a method of evaluating the 
growth fitness of two viruses (39;126). In the present study, we inoculated a ferret with 
equal doses of oseltamivir-sensitive and -resistant H1N1/2009 viruses to compare their 
relative growth fitness within the host. The mixed virus population in the nasal wash was 
analyzed at different days p.i. to determine which viral genotype predominated. To 
bypass the time- and labor-intensive process of cloning the desired genes from the mixed 
populations and choosing an arbitrary number of clones for genotypic analysis, we used a 
new method, relative quantification of SNP, to determine the ratio of wild-type to mutant 
populations. This method showed high reproducibility in genotyping HIV protease gene 
(126). Our study is the first to use this method to genotypically analyze influenza viruses. 
For the H1N1/2009 influenza viruses, we designed a specific probe to detect the first 
nucleotide of codon 275 of the NA gene, where a single C-to-T substitution causes an 
H-to-Y amino acid substitution. Our results showed that the oseltamivir-resistant mutant 
H1N1/2009 virus possessed less growth fitness than the sensitive H1N1/2009 virus in the 
ferret upper respiratory tract. At least partly for that reason, only wild-type H1N1/2009 
virus was transmitted to the direct-contact ferrets. The competitive transmission 
advantage of wild-type H1N1/2009 virus should be confirmed by other types of 
experiments. 
 
In summary, our study determined the comparative transmissibility of a pair of 
naturally circulating oseltamivir-sensitive and oseltamivir-resistant H1N1/2009 viruses. 
This information from this study could be useful in assessing the clinical relevance of 
contemporary pandemic viruses, considering the extensive use of oseltamivir during this 
pandemic. The H275Y mutant of H1N1/2009 used in this study was the first 
oseltamivir-resistant H1N1/2009 isolate from a patient on oseltamivir prophylaxis. As 
this study was undertaken, additional H275Y mutants of H1N1/2009 viruses have 
emerged in the absence of oseltamivir use (114;127). The emergence of these viruses 
should raise concerns as to whether resistant H1N1/2009 viruses will acquire 
significantly greater fitness and spread worldwide as did the naturally resistant H1N1 
viruses during the 2007-2008 season. Further studies of these newly isolated H275Y 
mutants of H1N1/2009 viruses are warranted to determine whether they have acquired 
additional changes. 
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CHAPTER 3.     THE MOLECULAR BASIS OF NATURALLY-OCCURRING 
OSELTAMIVIR-RESISTANT H1N1 INFLUENZA A VIRUSES 
 
 
Introduction 
 
The neuraminidase (NA) inhibitors (oseltamivir and zanamivir) are among the 
first line of defense against influenza infection. At present, two classes of antiviral drugs 
are approved for specific management of influenza: M2-ion channel blockers 
(amantadine and rimantadine) and neuraminidase (NA) inhibitors (zanamivir and 
oseltamivir) (28). However, variants resistant to both classes of drugs have emerged. 
Since 2007 season, most circulating seasonal H3N2 influenza viruses, varying portions of 
seasonal H1N1 viruses and avian influenza viruses of different subtypes, and almost all 
tested 2009 pandemic H1N1 viruses were reportedly resistant to M2-blockers (29;73). 
Therefore, only the NA inhibitors are currently recommended for treatment of influenza. 
 
The resistance to NA inhibitors can significantly limit the infection control 
options for influenza, so the susceptibility of circulating human influenza viruses to NA 
inhibitors has been closely monitored. Since the NA inhibitors were approved for clinic 
use in 1999, the resistant variants had emerged and the resistance detection rates had a 
radical change over the past decade (42;45;56). Until 2007, both the clinical observations 
and surveillance data indicated only sporadic, rare detection rate of resistance to NA 
inhibitor mainly under drug selection pressure (41;46;48), suggesting extremely low 
prevalence of resistance among circulating influenza viruses and no evident transmission 
of resistant viruses. However, the situation changed dramatically during the 2007-2008 
season, when seasonal H1N1 influenza viruses carrying the common 
oseltamivir-resistance NA mutation H275Y (274 in N2 numbering, 275 in N1 numbering) 
were detected with high prevalence in first the northern (57;58) and then the southern 
hemispheres (59) with no link to oseltamivir use. In the early 2009 season, almost 100% 
of H1N1 virus isolates tested in the USA were found to carry this resistant marker (60). 
The resistant variants were clearly becoming the dominant strain until the 2009 H1N1 
pandemic took over the world (56;128). Naturally-occurring oseltamivir-resistant or 
naturally resistant H1N1 viruses have been used to specifically refer to these seasonal 
H275Y mutant resistant H1N1 variants which were detected under the contexts of 
absence of oseltamivir use during the 2007~2009 seasons, in differentiation with the 
drug-selected viruses isolated from patients treated with NA inhibitors. 
It has remained puzzling for a long time how these naturally-resistant H275Y 
mutant viruses acquired optimal fitness because the previous experimental and 
epidemiologic data suggested otherwise (54;55). Two pioneering works on the naturally 
H275Y mutant H1N1 viruses significantly advanced the understanding to this question 
from two different angles (67;68). The visionary work by M.A Rameix-Welti et al (68),  
for the first time, revealed the distinct level of NA enzyme affinity and distinct cluster 
patterns of NA and HA genes of wild-type and H275Y mutant viruses among the older 
and new isolates of seasonal H1N1 viruses. In line with this study, subsequently, some 
phylogeny studies classified the specific cluster patterns of the NA and HA genes as 
different clades and showed the same trends that vast majority of H275Y mutant H1N1 
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viruses, especially the naturally resistant ones, commonly belonged to the Clade 2B (62-
66). Further studies have associated the higher enzyme affinity in some Clade 2B viruses 
to certain NA amino acid substitutions (63;69) and one study confirmed the role of NA 
D344N substitution in NA enzyme affinity (70). Another pioneering work by Bloom J. D 
et al (67), for the first time discovered that surface accumulation of a NA protein was 
reduced by the H275Y mutation and this defect could be corrected by two permissive 
mutations Q222R and V234M which appeared prior to the H275Y mutation in the NA 
evolution. This study is of significance to be the first to move the understanding of the 
defect by the H275Y mutation to NA protein expression level and firstly proposed the 
concept for the “permissive” mutations for H275Y mutation from the perspective of gene 
evolution. Following this findings, a recent study confirmed that the substitutions of the 
identified “permissive” residues into the “unpermissive” residues in the NA gene of a 
recent Clade 2B virus compromised the H275Y mutant virus replication in vitro and in 
vivo (71). 
 
These studies have provided insights to understand the defects in NA protein and 
virus caused by the H275Y NA mutation and how permissive NA mutations can 
counteract such defects in NA protein. However, because NA proteins play essential roles 
in influenza virus normal life cycle, it has been hypothesized that the permissive 
mutations may not only restore the defect caused by the H275Y mutation, but also may 
have extended roles beyond what were seen in H275Y mutant viruses (129). A simple but 
fundamental question remains open: what were the potential fundamental changes in the 
of seasonal H1N1 viruses other than H275Y mutant viruses during the first decade of 
oseltamivir use. So far no study had been done to learn about the wild-type H1N1 viruses 
themselves including NA protein function in vitro and virus fitness in vivo.  
 
This present study had started with aims to systematically characterize the virus 
fitness in vivo and NA phenotypes in vitro of genetically divergent seasonal H1N1 
viruses based on the NA phylogeny, also to comprehensively assess which and how the 
NA amino acid substitution in the NA gene divergence can affect the phenotype. To our 
surprise, the two “permissive mutations” enabling the H275Y mutation was consistent 
with our results but two mutations were only half of the growing list of permissive 
mutations, and even the “permissive mutations” for the H275Y mutation was only part of 
the whole story of NA protein evolution. Our results revealed that the natural NA genetic 
divergence led to significant phenotypic changes of the NA proteins themselves at many 
aspects, which in return determined the differential effects of the H275Y mutation on the 
NA proteins. Further study in combination with timeline analysis of the fixation of the 
divergent NA amino acid residues allow us to proposed a scenario for emergence of the 
naturally resistant viruses: during the seasonal H1N1 virus evolution, there were 
subsequent two lineages of H1N1 viruses with NA proteins of distinct attributes at 
protein level; the H275Y mutation had detrimental effects on protein expression and 
function of the old lineage NA proteins, which it only caused a minimal negative effects 
on the new lineage NA proteins; as results, the H275Y mutant H1N1 viruses of old 
lineage were extinguished due to severely compromised virus fitness, while the H275Y 
mutant viruses of new lineage were kept in continuing circulation due to minimally 
altered virus fitness – the naturally resistant H1N1 viruses. 
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Results 
 
 
Evolution of NA Genes of Seasonal H1N1 Influenza Viruses 
 
We firstly assessed the overall genetic difference of the NA genes of seasonal 
H1N1 viruses by examining their evolution history with a focus on NA H275Y variants 
isolated from 1999 to 2009 season. The phylogenetic analysis shows that the NA genes 
between 1999~2009 can be classified into four distinct lineages (Fig 3-1): New 
Caledonia/20/99-like (NC99-like), Solomon Island/23/06-like (SI06-like), 
Brisbane/59/07-like (BR07-like), and /Colorado/UR06-0053/2007 (CO07-like), 
corresponding to the classification of Clade1, Clade2A, Clade2B, Clade2C in previous 
reports (63-66). The tree also shows that the vast majority of NA H275Y variant isolates 
accumulate at the BR07-like lineage, and only a few H275Y isolates sparsely scatter at 
the NC99-like lineage (Fig 3-1). This observation is consistent with the previous 
surveillance studies of NA inhibitor susceptibility (63-66). To find the essential 
underlying difference between the two lineages, we compared the NA consensus 
sequences of both wild-type and H275Y mutant viruses from the BR07-like and 
NC99-like lineages. The comparison revealed that apart from the resistance-associated 
H275Y mutation, there are only ten amino acid residues substitutions differentiating the 
NA genotype between the BR07-like and NC99-like lineages (Table 3-1).  It is 
noteworthy that there is one predominant amino acid substitution (D354G) between the 
NA genes of wild-type and H275Ymutant viruses within the BR07-like lineage, and it is 
a reversion of the G354D substitution between the NC99-like and BR07-like lineages. 
We mapped the positions of the ten amino acid residues into a N1 molecule structure (Fig 
3-2), and found that none of them are located at the NA enzyme active site. The position 
45 and 78 are located at stalk region of NA molecule (not shown in the structure view); 
the position 222, 234, 249 and 344 are located on the periphery of the active site, and the 
position 214, 287, 329, 354 are located more distant from the active site.  
 
In order to reveal if there are any fundamental differences in the phenotypes of the 
H1N1 viruses, we then selected certain wild-type and H275Y mutant viruses from both 
the BR07-like and NC99-like lineages for subsequent characterization in vivo and in 
vitro. We chose viruses of NA genes of different molecular features for further 
comparison, with some being totally in agreement with the corresponding consensus 
residues at the ten positions and some possessing non-consensus residues at one or two 
positions. The alignments of the NA protein sequences of the selected H1N1 viruses with 
their corresponding consensus amino acid residues at ten positions are listed (Table 3-2).  
For example, the wild-type BR/59/07 and MEM/13/06 viruses, and the H275Y mutant 
NY/1692/09 and GA/20/06 viruses are fully in agreement with their corresponding 
consensus residues at all ten positions; while H275Y mutant HW/28/07, NY/3467/09, 
MI/03/02 viruses differ in their corresponding consensus residues at one or two positions 
respectively. 
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Figure 3-1. Evolution of NA genes of human seasonal H1N1 influenza viruses.  
 
Representative strains of seasonal human H1N1 influenza viruses from 1999-2009 were 
chosen for construction of the tree. Seasonal H1N1 virus vaccine strains among the years 
are filled by green color, and viruses reported to carry the H275Y NA mutation are filled 
by red color. The phylogenetic analysis was based on alignment of coding sequences of 
the N1 NA gene. The tree was constructed by using the neighbor-joining method (Kimura 
two-parameter) with 1000 bootstrap replicates in the Mega4 program. Only bootstrap 
values > 50 are shown. The bar represents 0.002 nucleotide substitutions per site. 
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Table 3-1. Comparison of the amino acid consensus sequences of NA genes of 
human seasonal H1N1 viruses of different lineages. 
 
H1N1 virus 
lineage 
NA genotype 
(275 position)a 
NA consensus amino acid residueb 
275 45 78 214 222 234 249 287 329 344 354
BR/59/07-like wild-type H N W G Q M K I E N D 
 H275Y mutant Y - - - - - - - - - G 
NC/20/99-like wild-type H H K E R V G T K D G 
 H275Y mutant Y - - - - - - - - - - 
 
a Indicate the amino acid residue at the 275 position of NA protein. 
b In the table, the symbol “-” indicates the amino acid residue in the mutant viruses is the 
same as the residue in the wild-type virus in the group. 
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Figure 3-2. The structure of NA monomer (N1 subtype) showing the 275 position 
and the 10 positions at which the amino acid substitutions differentiate the NAs of 
NC99-like and BR07-like. 
 
Surface-filling model of the neuraminidase protein of A/California/04/09 virus (PDB 
3NSS) shows the location of the 8 positions of amino acid residues listed in the Table 3-
1. Position 45 and 78 are located in stalk region of NA molecular, which is no included in 
this protein structure.  Both the top view and side view of the NA globular head were 
showed for the same 8 positions. The respective residues at the 10 positions are labeled in 
green and residue 275 is labeled in red which confers resistance to oseltamivir by the H to 
T mutation. The structure view was generated by PyMOL software. 
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Table 3-2. Agreement of the NA genes of the H1N1 viruses with the respective NA 
censuses sequences of human H1N1 viruses of different lineages at the 10 amino acid 
positions plus the 275 position. 
 
H1N1 virus  
lineages and strains 
(genotype at NA 275 
position)a 
NA amino acid residueb 
275 45 78 214 222 234 249 287 329 344 354
Seasonal BR07-like            
wild-type consensus H N W G Q M K I E N D 
BR/59/07 (wt) - - - - - - - - - - - 
CA/27/07 (wt) - - - - - - - - - - - 
H275Y variant consensus Y N W G Q M K I E N G 
HW/28/06 (H275Y) - - - - - - - - - - D 
NY/3467/09 (H275Y) - - - - - - - - - D - 
NY/1692/09 (H275Y) - - - - - - - - - - - 
NJ/15/07 (H275Y) - - - - - - - - - - - 
Seasonal NC99-like            
wild-type consensus H H K E R V G T K D G 
MEM/13/06 (wt) - - - - - - - - - - - 
GA/17/06 (wt) - - - - - - - - - - - 
MI/03/02 (wt) - - - - Q - - - - N - 
H275Y variant consensus Y H K E R V G T K D G 
GA/20/06 (H275Y) - - - - - - - - - - - 
MI/03/02 (H275Y) - - - - Q - - - - N - 
TX/30/07 (H275Y) - - - - - - - - - - - 
2009 pandemic H1N1            
wild-type consensus H Q Q D N V G E N N G 
DM/524/09 (wt) - - - - - - - - - - - 
H275Y variant consensus Y Q Q D N V G E N N G 
DM/528/09 (H275Y) - - - - - - - - - - - 
 38 
Table 3-2. (Continued). 
 
a Indicates the amino acid residue at the 275 position of NA protein. 
b In the table, the “-” symbol indicates the amino acid residue in the mutant viruses as 
same as the residue in the wild-type virus in the group.
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Transmissibility of Different Seasonal H1N1 Viruses in Ferrets 
 
Transmissibility of wild-type and H275Y mutant BR07-like viruses in ferrets. 
Transmissibility is considered as one of the most important clinical relevant properties of 
influenza viruses, so we firstly assessed the transmissibility of the H1N1 viruses in a 
ferret model. Four strains of BR07-like viruses were studied. The BR/59/07 virus is a 
representative wild-type virus for this lineage, which is shown as the immediate ancestor 
for the majority of H275Y mutant viruses that emerged between 2007~2009 (Fig 3-1). 
The other three viruses share the same lineage as the BR/59/07 virus but harbor the NA 
H275Y resistance marker and carry different NA molecular features: the NA gene of 
NY/1692/09 virus is fully in agreement with the BR07-like consensus residues at the ten 
positions, but the NA genes of HW/28/07 and NY/3467/09 virus differ in their consensus 
residues at the 354 and 344 position respectively (Table 3-2).  
 
We assessed the transmissibility of the four viruses in ferrets by both 
direct-contact route and respiratory-droplet route. In this model for each virus group, 3 
ferrets were intra-nasally inoculated with the same infectivity amount of the virus (donor 
ferrets), then one naïve ferret was housed with each donor ferret in the same cage 
(direct-contact route) at day 1 post-inoculation (p.i.), and another naïve ferret was placed 
in an adjacent cage separated from the donor’s cage by two layers of perforated divider 
(respiratory-droplet route) at the same time. Transmission of the viruses was assessed by 
detection of infection in recipient ferrets (nasal wash titers, clinical signs, and 
sero-conversion). 
 
As regards to the donor ferrets, in each of the four virus groups, the intranasal 
inoculation of the viruses resulted in successful infection in all donor ferrets (3/3) by 
nasal wash titers and sero-conversion (Fig 3-3A, Table 3-3). The donor ferrets shed virus 
productively with comparable peak virus titers and shedding duration among all 4 virus 
groups. The donor virus shedding at day1 post infection (p.i) were further analyzed, 
because day1 p.i was the time when the recipient ferrets were housed with the donors, 
and the level of the donor shedding might indicate the level of environmental virus 
exposure to the recipient ferrets at the time. Among all 4 virus groups, at day1 p.i only 
donor ferrets in the NY/3467/09 virus group had slightly lower shedding (1.5 
log10TCID50 lower) than the wild-type virus group, and the other 2 virus groups had 
shedding titers comparable to the wild-type virus group (Fig 3-3A, Table 3-3). 
 
Regarding to the direct-contact recipient ferrets, in each of the four virus groups, 
all the co-caged recipient ferrets (3/3) acquired infection from their donor ferrets through 
direct-contact transmission route, as shown by productive virus shedding over time and 
confirmed by sero-conversion in the each ferret (Fig 3-3A, Table 3-3). But the efficiency 
of acquisition of infection at day 1 post contact (p.c) was not entirely the same among the 
different groups (Fig 3-3B, Table 3-3). In the wild-type BR/59/07 virus group all 3/3 
ferrets acquired infection at day 1 p.c with high virus titers. In the HW/28/07 virus group, 
only 2/3 ferrets acquired infection at day 1 p.c with one ferret of lower titer than the 
wild-type group (~2 log10TCID50 lower). In the NY/3467/09 virus group, 3/3 ferrets 
acquired infection at day 1 p.c with one ferret of lower titer than the wild-type group (~2 
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Figure 3-3. Transmissibility of the seasonal H1N1 influenza viruses of two lineages 
in ferrets. 
 
(A) The virus titer in the nasal wash samples from each donor (black), direct-contact 
(DC) recipient (blue), and respiratory-droplet (RD) recipient ferret (red) over the sample 
collection time of 2 weeks. Each graph represents each different virus. The donor ferret 
was housed with recipient ferrets at day1 p.i. (B) The virus titers at day 1 p.i in nasal 
wash samples of the DC ferrets in different virus groups. Each dot represents individual 
donor ferret in the virus group. (C) The virus titers in the nasal wash samples of first 
detection of virus in the RD ferrets in different virus group. The day p.i of first detection 
of virus in each group is indicated. * p<0.05 by t test when compared with MEM13 
group.
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Table 3-3.  Detection of virus replication and sero-conversion in ferrets during transmission of the H1N1 influenza 
viruses. 
 
H1N1 viruses 
(NA genotype)a 
Inoculated donors Direct-contact recipients Respiratory-droplet recipients
Virus 
sheddingb
Duration 
of 
sheddingc
Serum HI
titerd 
Virus 
sheddingb
Duration 
of 
sheddingc 
Serum HI
titerd 
Virus 
sheddingb
Duration 
of 
sheddingc
Serum HI
titerd 
BR/59/07-like          
BR/59/07 (wt) 3/3 (6.3/7.1)
6      
(6,6,6) 
2560, 1280, 
1280 
3/3 
(3.0/6.9 )
7 
(7,7,7) 
2560, 2560, 
1280  
2/3 
(6.0) 
5 
(5, 5) 
320, 1280, 
<10 
HW/28/06 (H275Y) 3/3 (6.3/7.6)
6 
(6,6,6) 
2560, 2560, 
1280 
3/3 
(1.8/7.2)
6.3 
(5,7,7 ) 
2560, 2560, 
2560 
2/3 
(6.25) 
5 
(5, 5) 
1280, 
2560, <10
NY/3467/09 (H275Y) 3/3 (5.3/8.0)
6 
(6,6,6) 
640, 640, 
1280 
3/3 
(2.9/7.1)
7 
(7,7,7) 
1280, 2560, 
1280 
2/3 
 (6.1) 
6 
(7, 5) 
640, 640, 
<10 
NY/1692/09 (H275Y) 3/3 (7.0/7.2)
6 
(6,6,6) 
2560, 1280, 
2560 
3/3 
(4.6/6.3)
5.7 
(5, 5, 7) 
1280, 2560, 
1280 
2/3 
(5.9) 
5 
(5, 5) 
2560, 
2560, <10
rgBR/59/07 viruses          
rgBR/59/07-NAH275Y 3/3 (5.8/7.1)
6 
(6,6,6) 
2560, 2560, 
2560 
3/3 
(1.2/7.1)
5.7 
(5, 5, 7) 
2560, 640, 
2560 
2/3 
(6.75) 
6 
(5, 7) 
2560, 
1280, <10
rgBR/59/07-NAH275Y+D354G 3/3 (5.9/7.1)
6 
(6,6,6) 
2560, 1280, 
2560 
3/3 
(2.9/7.2)
7 
(7, 7,7) 
2560, 1280, 
2560 
2/3 
(6.75) 
7 
(7, 7) 
1280, 
1280, <10
NC/20/99-like          
MEM/13/06 (wt) 3/3 (6.6/8.0)
6      
(6,6,6) 
2560, 2560, 
2560 
3/3 
(3.7/7.4)
7 
(7, 7, 7) 
2560, 2560, 
2560 
2/3 
(6.1) 
5 
(5, 5) 
1280, 
1280, <10
MI/03/02 (H275Y) 3/3 (5.1*/6.9)
6      
(6,6,6) 
640, 1280, 
1280 
3/3 
(0.3*/6.7)
6.3 
(7, 5, 7) 
640, 1280, 
1280 
1/3 
(6.3) 
3 
(3) 
320, <10, 
<10 
GA/20/06 (H275Y) 3/3 (3.5*/6.8)
6      
(6,6,6) 
640, 1280, 
1280 
3/3 
(0.7*/6.2)
7 
(9,5,7) 
640, 640 
1280 
1/3 
(7.0) 
5 
(5) 
320, <10, 
<10 
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Table 3-3. (Continued). 
 
a Indicates the amino acid residue genotype at the 275 position of NA protein either as wt (wild-type H275) or H275Y 
mutation. 
b Number of virus-shedding animals/total number. Numbers in parentheses indicate mean virus titer at day1 p.i / mean peak 
virus titer in nasal wash samples (log10TCID50/ml, n=3). 
c The number of the days from the first day of detection of virus titer till the last day of detection of virus titer. Numbers in 
parentheses indicate days for each individual ferret in the group.  
d Hemagglutination inhibition (HI) antibody titers to homologous virus in ferret serum on day 21 p.i. Numbers indicate the HI 
titer of each individual ferret in the group.  
* Compared with the value in MEM/13/06 virus group, p<0.05, t test.
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log10TCID50); while in the NY/1692/09 virus group, 3/3 ferrets acquired infection and all 
had higher titers than the wild-type group (~1.5 log10TCID50 higher). Nevertheless, in 
spite of the differences in the acquisition of infection at day 1 p.c, all the direct-contact 
ferrets reached comparable levels of peak virus shedding among the different groups. The 
results suggested that both the BR07-like wild-type and H275Y mutant viruses were 
easily transmitted to recipient ferrets through direct-contact route, although the efficiency 
of the transmission of the H275Y mutant viruses  varied from slightly lower, higher, or 
similar efficiency than that of the wild-type BR/59/07 virus group. 
   
As for the respiratory-droplet recipient ferrets, in each of the four virus groups, 
only 2/3 recipient ferrets acquired infection from donor ferrets through 
respiratory-droplet transmission, as shown by productive virus shedding in the nasal 
washes and also confirmed by sero-conversion (Fig 3-3A, Table 3-3). 1/3 ferrets in each 
group did not acquire infection over the observation time, as indicated by lack of 
detection of virus shedding and sero-conversion. In general, compared with the 
direct-contact transmission, the respiratory-droplet transmission not only had relatively 
lower efficiency, but also had a greater lag time, varying from a delay of 2~6 days as 
indicated by the first day of detection of virus shedding. Furthermore, the dynamics of 
respiratory-droplet transmission into 2/3 ferrets was not entirely the same among the four 
virus groups (Fig 3-3C). The two ferrets acquired infection at day 3, and 7 p.c 
respectively in the wild-type BR/59/07 virus group as indicated by the first day of virus 
detection; day 3 and 5 p.c respectively in the HW/28/07 virus group and day 3 and 5 p.c 
respectively in the NY/3467/09 virus group, suggesting similar dynamics of transmission 
of these three viruses to that of the wild-type virus. In the NY/1692/09 virus group, both 
ferrets acquired infection at day 3 p.c, suggesting slightly faster transmission of this virus 
than that of the wild-type virus. Overall, the results together suggest that both the 
wild-type and H275Y mutant BR07-like viruses were able to be transmitted to recipient 
ferrets through respiratory-droplet route, but with lower efficiency and a greater lag time 
than direct contact-route; the H275Y mutant viruses were transmitted through 
respiratory-droplet route at similar efficiency or even slightly faster dynamics than the 
wild-type virus. 
  
Regarding clinical signs, all the infected ferrets (by inoculation or transmission) 
were observed with slight body weight loss (less than 5% of original body weight), 
spontaneous sneezing, fluctuated body temperature, but no obvious fever during the time 
of infection (data not shown). Among ferrets of the four virus groups there was no 
significant difference observed in these clinical signs, suggesting that both wild-type and 
H275Y mutant of BR07-like viruses caused a similar course of the disease with similar 
severity of the disease. 
 
In summary, these results suggested that compared to the wild-type BR07-like 
virus, the BR07-like H275Y mutant viruses were transmitted among ferrets by both 
direct-contact and respiratory-droplet routes at similar efficiency, with subtle variations 
in dynamics depending on the viruses; the H275Y mutant viruses also caused a similar 
course of disease with similar severity in donor and recipient ferrets as the wild-type 
virus.  
 44 
Transmissibility of reverse-genetics BR/59/07 viruses carrying H275Y NA 
mutation or/and D354G mutation. Reverse-genetics influenza viruses contain 
homogeneous genetic backgrounds with specified mutations on segments, thus allow 
precise evaluation the impact of the mutations on the virus.  We then assessed the impact 
of the H275Y mutation on the transmissibility of BR/59/07 virus by using 
reverse-genetics BR/59/07 (rgBR/59/07) viruses carrying different mutations. The two 
viruses were generated on the entire genetic background of the BR/59/07 virus. The first 
virus rgBR/59/07-NAH275Y differs only at the NA H275Y mutation from the wild-type 
BR/59/07 virus, which is similar to the NA genotype of HW/28/07 virus with regards to 
the NA consensus residues (Table 3-2). The second virus rgBR/59/07-NAH275Y+D354G had 
one more mutation D354G in addition to H275Y, which is similar to the NA genotype of 
NY/1692/09 virus with regards to the NA consensus residues (Table 3-2). The 
reverse-genetics viruses did not have differences in other genes, which was very likely in 
those H1N1 virus isolates. 
 
In both H275Y mutant virus groups, all the inoculated donor ferrets shed virus 
productively, with day 1 p.i virus titers, peak virus titer and duration of virus shedding 
comparable to those in the wild-type BR/59/07 virus group, suggesting no difference in 
the virus replication in ferret upper respiratory tract among these two viruses and the 
wild-type virus (Fig 3-3A, Table 3-3).  
 
With regards to direct-contact transmission, all recipient ferrets (3/3) in each 
group acquired infection from their donor ferrets, as indicated by productive virus 
shedding and sero-conversion (Fig 3-3A, Table 3-3), but the efficiency of acquisition of 
infection at day 1 p.c was distinct between the two groups (Fig 3-3B). In the 
rgBR/59/07-NAH275Y virus group, only 2/3 ferrets acquired infection at the time, with one 
ferret of lower virus titer than the wild-type virus group (~2 log10TCID50 lower) while in 
the rgBR/59/07-NAH275Y+D354G virus group, 3/3 ferrets acquired infection with titers 
approximate to those in the wild-type virus group. In spite of the shedding difference at 
day1 p.c, all the receipt ferrets reached comparable peak virus shedding. The results 
suggested that the H275Y mutation alone in the BR/59/07 virus minimally altered the 
efficiency of direct-contact transmission and only caused a slight delay at early 
transmission/infection stages, but the H275Y and D354G mutation together might negate 
such a delay and restore the same transmission efficiency as that of the wild-type 
BR/59/07 virus.  
 
As for respiratory-droplet transmission, only 2/3 ferrets in each virus group 
acquired infection. The efficiency of the transmission was the same as the wild-type virus 
group (Fig 3-3A, Table 3-3), but the dynamics of the transmission were slightly different 
(Fig 3-3C). In the rgBR/59/07-NAH275Y virus group 2 ferrets acquired infection at day 3, 
7 p.c respectively as indicated by first day of detection of virus shedding, which was the 
same as those in wild-type BR/59/07 virus group, while in the rgBR/59/07-NAH275Y+D354G 
virus group 2 ferrets acquired infection at day 3, 5 p.c respectively, which was slightly 
faster than those in the wild-type or the H275Y mutation virus groups. The results show 
that the H275Y NA mutation alone minimally affected the efficiency and dynamics of 
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respiratory-droplet transmission of the BR/59/07 virus, and the D354G and H275Y 
mutations together might slightly facilitate the transmission.  
 
In summary, by using the reverse-genetic viruses, we showed that the H275Y 
mutation alone hardly compromised the productive transmission of the BR/59/07 virus by 
both direct-contact and respiratory-droplet routes, although the dynamics of the 
transmission could be slightly altered. The D354G, a NA mutation of high frequency 
(>95%) in H275Y mutant viruses, together with H275Y mutation might slightly facilitate 
the virus transmission by both routes. Thus, the D354G mutation was somewhat 
beneficial for overall transmission of rgBR/59/07 virus with the H275Y mutation alone. 
As for clinical signs in the infected ferrets, there was no apparent difference observed 
among the three virus groups. Notably, the efficiency and dynamics of transmission of 
the rgBR/59/07-NAH275Y and rgBR/59/07-NAH275Y+D354G viruses were in line with those 
of HW/28/08 and NY/1692/09 viruses respectively, which are of similar NA genotype 
with regards to the consensus residues.  
 
Transmissibility of wild-type and H275Y mutant NC99-like viruses in ferrets. 
In comparison to the transmissibility of the BR07-like H1N1 viruses, we then studied the 
transmissibility of three strains of NC-99-like viruses in the ferret model. MEM/13/06 
virus is a representative wild-type virus for this lineage (Fig 3-1), which shares the same 
lineage as the NC/20/99 virus. Two other viruses also fall into the NC/99 lineage (Fig 
3-1), but harbor the H275Y NA mutation and carry different NA molecular features. The 
NA gene of GA/20/06 virus is fully in agreement with the consensus residues at the ten 
positions, while the NA gene of MI/03/02 virus differs at the 222 and 344 positions from 
the NC99-like consensus residues (Table 3-2).  
 
We evaluated the transmissibility of these viruses among ferrets by both 
direct-contact and respiratory-droplet route. The experimental settings and protocol were 
the same as described above for the BR/59/07-like viruses.  
 
As for the donor ferrets, in each of the three virus groups, the intranasal 
inoculation of viruses resulted in successful infection in all donor ferrets (3/3), as 
indicated by productive virus shedding and sero-conversion (Fig 3-3A, Table 3-3). The 
donor ferrets had comparable peak virus titers and virus shedding duration among all 
three virus groups, but both of the H275Y mutant GA/20/06 and MI/03/02 virus groups 
had significantly lower average virus titers than the wild-type virus group at day 1 p.i    
(~ 3 and 1.5 log10TCID50 lower respectively, p<0.05). The results suggest that the two 
NC/99-like H275Y mutant viruses had significantly delayed virus replication in ferret 
upper respiratory tract compared with the wild-type virus. 
 
With regards to direct-contact transmission in each of the three virus groups,  all 
recipient ferrets (3/3) acquired infection from their donor ferrets as indicated by virus 
shedding and sero-conversion (Fig 3-3A, Table 3-3), but the efficiency of acquisition of 
infection at day 1 p.c. was distinct among groups (Fig 3-3B). In the wild-type 
MEM/13/06 virus group, 3/3 ferrets acquired infection at day 1 p.c with high titers, but in 
both the GA/20/06 virus and MI/03/02 virus groups only 2/3 and 1/3 ferrets respectively 
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acquired infection at the time, with significantly lower virus titers than those in the 
wild-type virus group (~ 3 log10TCID50 lower, p<0.05). The results suggested that both 
NC/99-like H275Y mutant viruses had significantly delayed direct-contact transmission 
than the wild-type virus.  
 
Regarding to respiratory-droplet transmission, in the wild-type MEM/13/06 virus 
group, 2/3 recipient ferrets acquired infection from donor ferrets at day 3, 5 p.c 
respectively as indicated by the first day of virus detection in nasal washes (Fig 3-3A, 
Table 3-3). However, in both GA/20/06 virus and MEM/13/06 virus groups only 1/3 
recipient ferrets acquired infection and the other two recipient ferrets were not able to 
acquire infection during the whole observation time, as indicated by lack of detection of 
virus shedding and sero-conversion. Moreover, in the two H275Y mutant virus groups, 
the one infected recipient ferret acquired infection at day 7, 9 p.c. respectively (Fig 3-3C). 
This was considerably more delayed than the day 3 or 5 p.c in the wild-type virus group. 
The results suggested that the NC99-like H275Y mutant viruses were transmitted with 
considerably less efficiency than the wild-type virus through respiratory droplet route.  
 
In summary, the results suggested that compared to the wild-type virus, the 
replication of NC99-like H275Y mutant viruses by inoculation in the ferret upper 
respiratory tract was significantly delayed at early stage, and transmission of the 
NC99-like H275Y mutant viruses in ferrets was considerably less efficient and slower 
than the wild-type virus by both direct-contact and respiratory-droplet routes. 
 
Notably, when the NC99-like and BR07-like groups are compared, the 
transmissibility of the NC99-like wild-type virus was indistinguishable to its counterpart 
BR07-like wild-type virus, while the transmissibility of the NC99-like H275Y mutant 
viruses was remarkably reduced in terms of transmission efficiency and dynamics by 
both routes when compared with their counterpart BR07-like H275Y mutant virus.  
 
 
Growth Capability of Different Seasonal H1N1 Viruses in Cell Culture 
 
Virus growth capability is another important overall virus characteristic of 
influenza viruses, so we evaluated single-cycle growth of the BR07-like and NC99-like 
H1N1 viruses in NHBE cells. NHBE cells grow and differentiate on air-liquid interfaces 
and support influenza virus growth without the addition of TPCK trypsin, making them 
the best representation of epithelial cell lining in the respiratory tract. All the four 
BR07-like viruses used in the transmission study were evaluated for their growth 
capabilities. Two pairs of NC99-like viruses, which had NA genes only differing at the 
275 position within each pair, were evaluated for virus growth capabilities. In NHBE 
cells, for the BR07-like virus group (Fig 3-4), all three H275Y mutant viruses eventually 
grew to peak titers comparable to the wild-type virus at 12 hours p.i, although one virus 
HW/28/07 had delayed growth. In contrast, for the two pairs of NC99-like viruses (Fig 
3-4), both the H275Y mutant viruses only grow to titers significantly lower than their 
counterpart wild-type viruses by 12 hours p.i (~2 log10TCID50 lower, p<0.05). 
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Figure 3-4. Growth capability of different H1N1 viruses in NHBE cells. 
 
Single-cycle growth curves of different H1N1 viruses in MDCK cells were obtained by 
using an MOI of ~2 PFU/cell, respectively. Wild-type viruses are drawn in black solid 
lines and H275Y mutant viruses are drew in grey dashed lines. Virus in the supernatant 
was titrated in MDCK cells and expressed as log10TCID50/ml at the indicated time 
post-infection (p.i). Each point represents the mean value ± SD from three replicates. 
* p<0.05 by t test, compared with the respective wild-type virus at the same time point. 
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We also examined the plaque morphology by these H1N1 viruses in MDCK cells. 
Most viruses showed heterogeneous plaque sizes, and overall, the BR07-like viruses 
generated bigger plaques than the NC99-like viruses regardless of the H275Y mutation 
(data not shown), which is in agreement with previous reports on plaque morphology of 
H1N1 viruses (61). 
 
Taken together, the results showed that in the cells, the growth capability of the 
BR07-like H275Y mutant viruses was approximate to their counterpart wild-type virus 
although with variations. In contrast, the growth capability of the NC99-like H275Y 
mutant viruses was considerably attenuated when compared with their counterpart 
wild-type viruses. 
 
 
NA Enzyme Activity, Protein Expression and Enzyme Kinetics of Different Seasonal 
H1N1 Viruses in vitro 
 
Generation and characterization of epitope-tagged recombinant NA proteins. 
In order to understand if the difference in transmissibility and infectivity of the 
characterized H1N1 viruses was associated to the NA enzyme function in the viruses, we 
assessed the NA enzyme activities of the BR07-like and NC99-like H1N1 viruses in vitro 
using a fluorescence-based substrate. When the whole virus particles standardized by the 
same infectivity were used for the assay, the results showed no significant difference of 
NA activity among different lineages, and failed to give any discernable trend among 
different groups (data not shown), which is in agreement with a previous report that no 
difference was found among the NA activities of wild-type and H275Y mutant H1N1 
viruses (68). We speculated that the reason that such results were not informative could 
root in two major flaws about using whole virus particles for the assay: 1) virus particle 
quantitation can never be accurate enough and the errors masked the potential difference, 
as replication defective particles cannot be measured in infectivity assays and the 
infectivity assays by themselves are inaccurate; 2) the amount of virus surface NA 
protein was not counted into the analysis even if the virus particles were standardized, as 
different amount of NA proteins can be incorporated into the virus particle driven by 
different M proteins or different expression levels of the NA protein themselves. In order 
to overcome both potential flaws, we sought to measure enzyme activity of the NA 
proteins rather than the whole virus particles, which need antibodies to recognize the NA 
proteins. Due to the lack of one kind of anti-NA antibodies that can recognize all the NA 
variants with the same binding affinity, we generated the recombinant NA proteins with 
the same epitope tag, which allow quantitation of different NA protein variants for the 
following activity assay. We chose the HA epitope tag for the recombinant NA protein as 
it was reported previously (67). 
 
We firstly assessed if the addition of the epitope tag to either NA protein terminus 
could affect the protein expression in cells (Fig 3-5). We generated the un-tagged, 
C-terminal tagged and N-terminal tagged recombinant proteins of the NA of BR59/07 
virus and compared their expression levels (Fig 3-5A). First off, the expression levels of 
either tagged proteins were in proportion to the amounts of the plasmids transfected into  
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Figure 3-5. Generation and characterization of epitope-tagged recombinant NA 
protein of BR/59/07 virus. 
 
(A) The detection of different tagged recombinant BR/59/07-NA protein in BHK cells by 
western blot. The amounts of respective plasmids for transfection are labeled 
accordingly. The upper panel is the detection by anti-HA tag antibodies, and the lower is 
by anti-Actin antibodies. (B) The NA enzyme activity of the different tagged 
recombinant proteins in cells expressed by 0.5 μg respective plasmids for transfection. 
The data were normalized to the untagged protein (100%). *  p< 0.05 by t test compared 
the untagged NA group. (C) The enzyme activity exhibited by untagged or C-terminal 
tagged proteins expressed by 0.5 and 1.5 μg respective plasmids. (D) The enzyme 
kinetics (Vmax at left Y axis and Km at right Y axis) exhibited by untagged or 
C-terminal tagged proteins expressed by 0.5 and 1.5 μg respective plasmids. 
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the cells. Secondly, the expression level of the N-terminal tagged NA protein was 
constantly much lower than that of the C-terminal tagged protein based on the density of 
the protein bands. The expression levels of the C-terminal tagged and untagged NA 
protein cannot be directly compared by protein detection, but NA enzyme activity 
measurement showed that the two proteins exhibited approximately equivalent activities 
(Fig 3-5B), suggesting equivalent protein expression levels between the two proteins. In 
contrast, the N-terminal tagged protein retained a significantly lower amount of activity 
than the untagged and the C-terminal tagged proteins (p<0.05) (Fig 3-5B), which is in 
agreement with the protein detection results (Fig 3-5A). The comparison suggested that 
the C-terminal HA epitope tag did not alter the level of the NA protein expression and 
activity, so the C-terminal epitope tag was chosen for generation of all recombinant NA 
proteins.  
 
Next, we examined the surface accumulation of the C-terminal tagged NA protein 
of BR/59/07 virus. During the life cycle of an influenza virus, the expressed NA proteins 
are reportedly transported to the cell surface to be incorporated into nascent virus 
particles. In order to make the results of NA protein expression mostly relevant to the 
levels of NA proteins incorporated into virus particles, we assessed the cell surface 
accumulation of the recombinant NA proteins. First of all, in the protein blot images, a 
relatively faint band was consistently found to accompany the major protein band (in 
either C- or N-terminal tagged protein images), and the density of the second band was 
always in proportion with its corresponding major band (Fig 3-5A). Considering their 
slightly higher molecular weight, presumably, the second protein bands could be the 
glycosylated NA proteins being transported to the cell surface. Secondly, we examined 
the cell surface accumulation of the NA proteins by flowcytometry (Fig 3-6). The results 
showed the accumulation of the C-terminal tagged NA proteins at the cell surface, and 
the accumulation intensity was in proportion to the amounts of the plasmids transfected 
into the cells. 
 
Furthermore, we characterized the function of the C-terminal tagged NA protein 
of BR/59/07 virus in comparison to the untagged NA protein. The enzyme activities 
exhibited by both proteins were proportionate with their protein expression levels (Fig 
3-5C), which were proportionate to the amounts of the plasmids transfected into the cells 
(Fig 3-5C). The enzyme properties Km and Vmax were determined for both the 
recombinant proteins (Fig 3-5D). Km is the dissociation constant for enzyme binding to 
the substrate, which is intrinsic to the enzyme and independent of the about of protein 
presented in the reaction; Vmax reflects catalytic capability of the enzyme and is 
dependent on both the enzyme turnover rate (Kcat) and the amount of enzyme present in 
the reaction. The results showed that both the C-terminal tagged, untagged NA proteins 
(Fig 3-5D), and whole virus particles exhibited comparable Km values (data not shown), 
despite different amounts of the proteins or virus particles used for the assays. Both the 
recombinant NA proteins exhibited comparable Vmax values, which were proportionate 
to their expression amounts (Fig 3-5A). The results suggested that the C-terminal tagged 
NA protein retained the enzyme properties indistinguishable to the untagged NA protein, 
and could represent the original NA protein properly.  
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Figure 3-6. The cell surface protein accumulation of C-terminal tagged BR07-NA 
protein.  
 
The detection of the surface accumulation of the BR07-NA protein by flowcytometry. 
The different lines indicate the protein accumulation expressed by different amount of 
plasmids for transfection, which was, from left to right, 0, 0.1, 0.5, 1.5 μg of the plasmids 
into cells.  
 52 
Enzyme activities of recombinant NA proteins of H1N1 viruses in vitro. Next, 
we generated and compared the C-terminal tagged recombinant NA proteins of different 
H1N1 viruses. All of the data were normalized to the activity of wild-type NA of the 
BR/59/07 virus (BR/59/07-NA) (Fig 3-7A). In the BR07-like group, the 5 different 
H275Y mutant NA proteins exhibited enzyme activities approximate to the BR/59-NA 
protein with small variations (Fig 3-7A); especially, the BR/59/07-NAH275Y protein 
exhibited a marginal loss (~20%, data not shown separately) of enzyme activity 
compared with the BR/59/07-NA protein, which only differs from each other at the 
H275Y mutation. However, in the NC99-like group, not only the 3 different wild-type 
NA proteins exhibited much lower activity than their wild-type counterpart BR/59/07-NA 
protein in the BR07-like group, but also the 3 different H275Y mutant NA proteins 
exhibited drastic losses of the activity (~50%) compared with the corresponding 3 
wild-type NA proteins (Fig 3-7A). Noted, the highest enzyme activities in either the 
wild-type or H275Y mutant NA proteins in the NC99-like group were from the MI/03/02 
viruses, which differ from the NC99-like consensus residues at the 222 and 344 positions 
(Table 3-2). 
 
Taken together, the results showed that the enzyme activities of BR07-like 
H275Y mutant NAs were minimally impaired compared to that of BR07-like wild-type 
NA, but the enzyme activities of the NC99-like H275Y NAs were severely diminished 
compared to those of their corresponding wild-type NAs, which were inherently-low by 
themselves. The results suggested that the enzyme activities of the wild-type NAs of the 
two different lineages are inherently distinct in the first place, and the H275Y mutation 
had differential effects on enzyme activity of the NAs of the two different lineages. 
  
Expression levels of recombinant NA proteins of H1N1 viruses in cells. 
Reduced enzyme activity of the NA proteins can directly result from a reduced 
expression level of the proteins in cells. We next examined the expression levels of the 
recombinant NA proteins of the H1N1 viruses (Fig 3-7B). The total expression levels of 
the NA proteins in cells were examined by western blot. In the BR07-like group, the 
respective expression of 5 different H275Y NA proteins were similar to that of the 
wild-type BR/59/07-NA protein although with slight variations based on the density of 
the protein bands (Fig 3-7B). Especially, the BR/59/07-NAH275Y protein showed minimal 
change of expression level compared with the BR/59/07-NA protein. However, in the 
NC99-like group each of the 3 H275Y mutant NA proteins showed greatly reduced 
expression levels compared with their counterpart wild-type NA proteins (Fig 3-7B). 
Additionally, when the NC99-like and BR07-like groups are compared, each of the 3 
NC99-like wild-type NA proteins showed naturally lower protein expression levels than 
the wild-type BR/59/07-NA respectively, and the 3 NC99-like H275Y mutant NA 
proteins showed greatly diminished protein accumulation compared with the BR07-like 
NA proteins.  
 
We further examined the cell surface accumulation of 4 pairs of NA proteins of 
different viruses (Fig 3-7C). In each pair, the two NA proteins only differ from each other 
at the 275 position. In the BR07-NA group, the protein accumulation profiles of the 
H275Y mutant NA proteins were overlapped together with that of the wild-type NA 
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Figure 3-7. The NA enzyme activities, protein expression levels and enzyme Km 
values of different seasonal H1N1 influenza viruses. 
 
(A) The enzyme activities of C-terminal tagged recombinant NA proteins of different 
H1N1 viruses. The data were normalized to the BR/59/07-NA. Each dot represents the 
mean value of three determinations of each different NA protein. The NA protein 
designations are entirely the same as in B panel. (B) The detection of the recombinant 
NA proteins of each virus by western blot. The upper panel is the detection by anti-HA 
tag antibodies, and the lower is by anti-Actin antibodies. (C) The detection of the cell 
surface accumulation of the 4 pairs of recombinant NA proteins by flowcytometry. Each 
panel is for each pair of NA proteins which only differs at 275 position in the pair (upper 
right BR/59/07 virus, upper left GA/17/06 and GA/20/06 viruses, lower right 
MEM/13/06 virus, lower left MI/03/02 viruses) .In each panel, the black line and the red 
line indicate the wild-type and the H275Y mutant NA protein respectively and two lines 
should be compared within each panel. (D) The NA enzyme Km value of different H1N1 
viruses. Each dot represents the mean value of three determinations of each virus, 
although the data were not shown separately.  
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protein (Fig 3-7C), suggesting that the surface accumulations of the two proteins were 
indistinguishable. However, in other three NC99-like NA groups, the profile of each 
H275Y mutant NA protein greatly shifted to the left compared to its counterpart 
wild-type NA protein in the pair (Fig 3-7C), suggesting their greatly diminished cell 
surface accumulation. The results of cell surface NA accumulation and were consistent 
with the results of total NA protein expression in cells, suggesting that the lower cell 
surface NA accumulation could directly result from its lower protein expression in the 
cells. 
 
Taken together, the results showed that both the total protein expression and the 
cell surface protein accumulation of the BR07-like H275Y mutant NAs were hardly 
altered compared with those of the BR07-like wild-type NA. However, both the total and 
surface protein accumulation of the NC99-like H275Y mutant NAs were greatly 
diminished compared with those of their counterpart NC99-like wild-type NAs. The 
results suggested that the protein expression level of the wild-type NAs of the two 
different lineages are naturally distinct in the first place, and the H275Y mutation had 
differential effects on the level of protein expression of the NAs of the two different 
lineages.  
 
NA enzyme kinetics of the H1N1 viruses in vitro. Reduced enzyme activity of 
NA proteins can also result from reduced functional capability of the NA enzymes. Two 
enzyme kinetic parameters measure enzymatic functional capability: Km and Vmax. Km 
is an estimate of the dissociation equilibrium of enzyme binding to the substrate, and the 
reciprocal of Km approximates the enzyme affinity to substrate binding; Vmax reflects 
the catalytic activity of the enzyme and is determined by the reactive amino acid residues 
at enzyme active site and the amount of enzyme. Since none of the variant NA residues 
between the H1N1 viruses are located at the active site and the NA protein expression 
levels have been evaluated, only Km (the dissociation constant) was further determined 
for evaluation of the NA enzyme affinity to substrate binding. 
 
In each of the BR07-like and NC99-like groups, all the H275Y mutant viruses 
exhibited higher average NA Km values than the wild-type viruses: ~50 μM vs ~ 20 μM 
in the BR07-like group and ~ 200 μM vs 100 μM in the NC99-like group (Fig 3-7D), 
indicating lower substrate binding affinity in these H275Y mutant NAs than those of their 
counterpart wild-type NAs. However, when the BR07-like and NC99-like groups were 
compared, the results showed the NA Km values of two groups were but at different 
levels, which were ~100 μM vs 20 μM between the NC99-like and BR07-like wild-type 
viruses, and were ~200μM vs 50 μM between the H275Y mutant viruses in two groups 
(Fig 3-7D), suggesting inherently-low enzyme affinity in the NC99-like NAs. Noted, the 
highest NA Km value in H275Y mutant viruses in the BR07-like group was from 
NY/3467/09 virus, which differs from its consensus residues at the 344 position (Table 
3-2). The lowest NA Km values in either wild-type or H275Y mutant viruses in the 
NC99-like group were from the MI/03/02 viruses, which differ from their consensus 
residues at two positions (Table 3-2). 
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Taken together, the results showed that the BR07-like H275Y mutant viruses had 
only slightly reduced NA enzyme affinities compared to their counterpart wild-type 
viruses due to the inherently-high level of NA affinity in this lineage. However, the 
NC99-like H275Y mutant viruses have greatly diminished NA affinities compared to 
their counterpart wild-type viruses due to the inherently-low level of NA affinity in this 
lineage. The results were consistent with but also further expanded previous reports 
(63;69;70),  suggesting that the enzyme affinity of the wild-type NAs of the two different 
lineages were inherently distinct in the first place, and the H275Y mutation had 
differential effects on the level of enzyme affinity of the NAs of two different lineages.  
 
To summarize the in vitro characterization of the NAs of different H1N1 viruses, 
between the BR07-like and NC99-like groups, with regards to the wild-type NAs, 
BR07-like NAs had naturally higher enzyme activities than the NC99-like NAs, due to 
the higher level of NA protein expression and NA enzyme affinity. Within the BR07-like 
group, compared to the wild-type NA, the H275Y mutant NAs had minimally impaired 
enzyme activities because of the minimally reduced naturally-high protein expression and 
enzyme affinities. Within the NC99-like group, compared with the wild-type NAs, the 
H275Y mutant NAs had greatly diminished enzyme activities, as a result of further 
reduced naturally-low NA protein expression and enzyme affinities. The results 
suggested that the H275Y mutation commonly had a negative effect on the NA protein 
expression and enzyme affinity, but the degree of effects could be minimal as in 
BR07-like NAs, or be drastic as in NC99-like NAs. In other words, the BR07-like NAs 
had tolerance to the H275Y mutation, but the NC99-like NAs had no tolerance to it.  
 
In summary of the in vivo and in vitro phenotype characterization of different 
H1N1 viruses, in the BR07-like virus lineage, the wild-type NAs were naturally-high in 
quantity (protein expression) and quality (enzyme affinity), so they could tolerate the 
negative effects of the H275Y mutation on the protein expression and enzyme affinity 
and the H275Y mutant NAs only had a marginal loss of NA activity; as a result, the 
H275Y mutant viruses were minimally compromised in terms of virus infectivity and 
transmissibility, and were allowed in the BR07-like lineage. However, in the NC99-like 
virus lineage, the wild-type NAs were inherently-low in quantity and quality, so they 
were not able to tolerate the deleterious effects of the H275Y mutation on the protein 
expression and enzyme affinity and H275Y mutant NAs had a great loss of NA activity; 
as a results, the H275Y mutant viruses were severely compromised in terms of virus 
infectivity and transmissibility, thus they were extinct in the NC99-like lineage. 
 
 
Effects of the Single Amino Acid Substitutions in BR07-NA Gene (from BR07-like to 
NC99-like) on Protein Function and Expression 
 
Effects of NA variants of different enzyme activities on plaque morphology of 
the reverse-genetics viruses.  Next, we sought to find the NA molecular basis for the 
distinct quantity and quality of NA proteins of the BR07-like and NC99-like lineages. We 
firstly chose two pairs of NA genes/proteins with one wild-type and another H275Y 
mutant to represent each lineage for subsequent in vitro characterization. The NA gene of 
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wild-type BR/59/07 virus (BR07-NA) and its H275Y variant acquired by mutagenesis at 
the 275 position (BR07-NAH275Y) were chosen to represent the BR07-like lineage. The 
NA genes of viruses GA/17/06 and GA/20/06 viruses (GA06-NA, GA06-NAH275Y) which 
naturally only differ at H275Y mutation were chosen to represent the NC99-like lineage.  
 
Since the two pairs of NAs (BR07 and GA06 pair) showed very contrasting levels 
of NA activity in vitro (Fig 3-5A, 2-6A), we further tested if the different levels of NA 
activity could affect the virus growth in terms of plaque size in MDCK cells. We 
generated the reverse genetic viruses by using the 7 segments (except the NA segment) 
from the BR/59/07 virus with the two pairs of NA genes respectively. Among the 4 
reverse-genetics viruses, BR07-NA generated big clear plaques (1.8 mm), without 
apparent reduction of the plaque size by the presence of H275Y mutation 
(BR07-NAH275Y) (1.8 mm) (Fig 3-8A, B); in contrast, GA06-NA only generated 
pinpoint-like small plaques (0.5 mm), and even smaller plaques with the presence of 
H275Y mutation (GA06-NAH275Y) (0.3 mm) (Fig 3-8A, B). In these reverse-genetics 
viruses, the virus absorption and replication by the same viral 7 proteins were totally the 
same and only the release and spread of progeny virus by different NA proteins was 
different, thus the plaque sizes can be associated with different function levels of the NA 
variants during virus growth in the cells. The results suggested that the plaque sizes of the 
reverse-genetics viruses, which only differed at the NA genes, were positively correlated 
with the levels of their NA enzyme activities. In other words, the lower NA activity, the 
smaller plaque size, and vice versa. 
  
Effects of the single amino acid substitutions (from BR07-like to NC99-like) 
in BR07-NA gene on plaque morphology of the reverse-genetics viruses. Based on the 
results that the level of NA activity can determine the plaque size of the reverse-genetics 
viruses, we took a “loss-of-activity” and “reduction-of-size” strategy to find the amino 
acid residues in the BR07-NA protein which are responsible for its high enzyme activity. 
We used the reduction of plaque size of reverse genetic viruses of NA variants as the first 
criteria to probe potential activity-reducing amino acid in the BR59-NA. There are only 
10 amino acid substitutions differentiating between BR07-like and NC99-like NAs 
(Table 3-1). We substituted each of the 10 amino acid residues in the BR07-NA gene 
with the corresponding NC99-like consensus residues respectively, as N45H+W78K, 
G214R, Q222R, M234V, K249G, I287T, E329K, N344D, D354G (the 45 and 78 
positions were placed together because they are the only two residues located in the stalk 
region of NA), with the absence or the presence of the H275Y mutation respectively, then 
we generated the reverse genetics viruses by using the 18 variants of the BR07-NA gene. 
The plaque assay in MDCK cells showed that regardless of the presence of the H275Y 
mutation, the majority of the substitutions did not cause an appreciable change in the 
plaque size of the viruses (Fig 3-8C), and only 4 respective substitutions (Q222R, 
M234V, E329K and N344D) resulted in significantly reduced plaque size in a different 
manner (p<0.05) (Fig 3-8C, Fig 3-9). Specifically, the Q222R and E329K caused 
drastically reduced plaque sizes of the viruses regardless of the H275Y mutation (0.7, 0.8 
mm respectively and 0.6, 0.7 mm respectively with the presence of the H275Y). The 
M234V or N344D alone caused a marginal change in the plaque sizes (1.5, 1.7 mm 
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Figure 3-8. The plaque sizes of rgBR/59/07 viruses containing different NA gene 
variants. 
 
(A) The plaque sizes (left Y axis) of rgBR/59/07 viruses using two pairs of NA gene 
variants (BR07 and GA06 pair), and the enzyme activities (right Y axis) of each pair of 
proteins. The diameters of 10 randomly selected plaques were measured. Values are 
mean plaque diameters (mm) ± SD * p<0.05 by t test between indicated groups. (B) The 
plaque morphology of the rgBR/59/07 (rgBR/59) viruses using two pairs of NA variants. 
(C) The plaque sizes of rgBR/59/07 viruses using 20 different NA variants of different 
single amino acid residue substitution with the absence (wt-H275) or the presence 
(H275Y) of the H275Y mutation. The mutations are indicated in each group.  
*, ** p<0.05 by t test when compared with rgBR59-wt-H275 or rgBR59-wt-H275Y 
respectively. 
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Figure 3-9. The plaque morphologies of rgBR/59/07 viruses of single amino acid 
residue substitutions in the NA gene. 
 
The plaque morphology of rgBR/59/07 viruses using 10 different BR07-NA gene 
variants of different single amino acid residue substitution with the absence (wt-H275) or 
the presence (mut-H275Y) of the H275Y mutation. The mutation sites are indicated 
above in each image. 
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respectively), but caused a greater reduction of the plaque sizes at the presence of the 
H275Y mutation (1.0, 0.9 mm respectively). The results suggested that the 4 amino acid 
substitutions which caused notable change of the virus plaque sizes could potentially 
cause decrease of the NA activity in the viruses. We chose these 4 NA amino acid 
positions for further evaluations, but acknowledged that the other 6 substitutions might 
also exert certain effects on the NA activity, but not big enough to cause a detectable 
change in the virus plaque size. The NA position 354 exhibited unique amino acid 
residue reversion (Table 3-1), so this position also was included along with other 4 
positions for future analysis.  
 
Effects of the single amino acid substitutions (from BR07-like to NC99-like) 
in BR07-NA gene on protein function and expression. We identified 4 amino acid 
substitutions in the BR07-NA gene causing reduction of the virus plaque sizes, so we 
proceeded to evaluate if the four substitutions caused loss of activity in the NA proteins 
and by which mechanism. We determined the enzyme activities of the 12 variant 
BR07-NA proteins of the single amino acid substitutions (Fig 3-10A). First, the H275Y 
mutation alone in the BR07-NA protein only caused a small decrease of the enzyme 
activity; secondly, each of the substitutions (Q222R, M234V, E329K, N344D) in the 
BR07-NA caused a significant decrease of the enzyme activity with a greater magnitude 
at the presence of the H275Y mutation (p<0.5), which were correlated with the reduced 
virus plaque sizes caused by these substitutions (Fig 3-8C). The D354G in the BR07-NA 
increased the enzyme activity which was opposite to other 4 substitutions (Fig 3-10C), 
although it did not cause a notable change in virus plaque size (Fig 3-8C).  
 
We tested the effects of each of the 5 amino acid residue substitutions on the 
protein expression and enzyme affinity of BR07-NA (Fig 3-10B). First off, The H275Y 
mutation alone in the BR07-NA caused minimal change in the protein expression; two 
substitutions (Q222R, M234V) in the BR07-NA severely ablated the level of protein 
expression, even to a lower level with the presence of the H275Y mutation; the other 3 
substitutions did not appear to affect the level of protein expression. Secondly, as regard 
to the effects on the NA enzyme affinity (Fig 3-10C);, the H275Y mutation alone in 
BR07-NA slightly increased the Km value three substitutions (Q222R, E329K, N344D) 
in the BR07-NA significantly raised the enzyme Km values (P<0.05), to a bigger degree 
with the presence of the H275Y mutation, while the D354G substitution in BR07-NA did 
not show any apparent impact on the Km values. The results together suggest that the 4 
substitutions in the BR07-NA reduced the NA activity by two different mechanisms, and 
only the Q222R played both roles. 
  
BR07-NA resulted in a slightly reduced unit activity, which can be associated 
with its slightly reduced enzyme affinity. Furthermore, the Q222R substitution in the 
BR07-NA led to a remarkably low unit activity with either the absence or presence of the 
H275Y mutation, so its dual role in protein expression and enzyme affinity explained the 
most drastic decrease of activity by this substitution. The M234V in the BR07-NA 
retained a similar level of unit activity, suggesting this substitution only reduced the 
protein expression, but not the enzyme affinity; both the E329K and N344D led to 
reduced unit activities to a greater magnitude with the presence of the H275Y mutation. 
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Figure 3-10. Effects of five different single amino acid substitutions in the BR07-NA 
genes on NA enzyme activity, km value and protein expression. 
 
(A) The enzyme activities of the variant BR07-NA proteins with 5 different single amino 
acid substitutions with the absence or presence of the H275Y mutation respectively. Each 
substitution is labeled below the graph. (B) The detection of the same variant BR07-NA 
proteins of the 5 single amino acid substitutions by western blot. The upper panel is the 
detection by anti-HA tag antibodies, and the lower is by anti-Actin antibodies. (C) The 
NA enzyme Km value of the rgBR/59/07 viruses of BR07-NA variants of the 5 single 
substitutions by enzyme kinetics assay. (D) The enzyme activity per unit of protein 
(random unit of gray-scale of protein band) of the variant BR07-NA proteins of the 5 
single substitutions. The data were calculated by using the enzyme activity of each NA 
variant divided by the protein quantity (measured as the density of the protein bands), and 
then the results were relative to the BR07-NA-wt. In all graphs, all values are the mean of 
3 determinations ± SD. *, **< 0.05 by t test when compared to BR/59 or BR/59-H275Y 
respectively.  
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The D354G in the BR07-NA was the only substitution increasing the unit activity, 
consistent with the increased enzyme activity above, but apparently not through the 
mechanism of enzyme affinity.  
 
In conclusion, by using a loss-of-activity strategy in the BR07-NA, we discovered 
that in the genetic background of the BR07-like NAs, one group of molecular markers 
(Q222 and M234 residues) functioned to keep the high level of NA protein expression, 
and another group of molecular markers (Q222, K249 and N344 residues) served to 
provide the high level of NA enzyme affinity to substrate binding. The two groups of 
markers not only maintained the high quantity and high quality of the BR07-like NAs, 
and more importantly, they also essentially counteracted the negative effects of the 
H275Y mutation on the protein expression and enzyme affinity, thus conferring the 
H275Y tolerance to the NA protein. In addition, the D354G substitution in the BR07-NA 
somehow increased the enzyme activity even with the presence of the H275Y mutation, 
by unidentified mechanism.  
 
 
Effects of the Reciprocal Single Amino Acid Substitutions in GA06-NA Genes (from 
NC99-like to BR07-like) on Protein Function and Expression  
 
Now that we identified 4 amino acid residues (Q222, M234, K249, N344) in the 
BR07-NA responsible for its high NA quantity and quality, we proceeded to tested if the 
reciprocal amino acid substitutions (from NC99-like to BR07-like) at the 4 positions in 
NC99-like NAs were able to restore the low quantity and quality of NC99-like NAs to 
the high level of BR07-like NAs. We substituted each of the 4 amino acid residues in the 
GA06-NA gene (NC99-like lineage) with the corresponding BR07-like consensus 
residues respectively, as R222Q, V234M, E329K and D344N, with the absence or the 
presence of the H275Y mutation. Then we generated the reverse-genetics viruses by 
using the 8 variants of the GA06-NA genes and compared them with the GA06-NA and 
BR07-NA derived viruses as described above. The GA06-NA naturally has G residue at 
the 354 position, so the D354G reversion was not counted into the analysis. The impact 
of each of the 4 substitutions in the GA06-NA gene on virus plaque size, enzyme activity, 
protein expression and enzyme affinity were examined and compared. 
 
As for the plaque size of the reverse-genetic viruses (Fig 3-11A, Fig 3-12), the 
GA06-NA gene generated pinpoint-like plaques owning to its low activities (0.5 mm) as  
showed above, and the H275Y mutation in the GA06-NA caused a further reduction of 
the inherently small plaque size (0.3 mm). Each of the 4 substitutions in the GA06-NA 
increased the virus plaque size respectively but to different magnitudes: the R222Q or 
E329K alone significantly increased virus plaque size (1.3 and 2.0 mm respectively, 
p<0.05) but to a slightly smaller degree with the presence of the H275Y mutation (1.1 
and 1.8 mm respectively). The V234M or D344N alone in the BR07-NA did not greatly 
change the virus plaque size (0.6 and 0.6 mm respectively), but with the presence of the 
H275Y mutation, both substitutions effectively prevented the further plaque size 
reduction by the H275Y mutation (0.6 and 0.5 mm respectively).  
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Figure 3-11. Effects of four different single amino acid substitutions in the GA06-
NA genes on plaque size of reverse-genetics viruses, NA enzyme activity, NA Km 
value and NA protein expression. 
 
(A) The plaque sizes of the rgBR/59/07 viruses by using 10 variants of GA06-NA genes 
with 4 different single amino acid substitutions at the absence or presence of the H275Y 
mutation respectively. The enzyme activities (B) and protein detections (C) of the variant 
GA06-NA proteins with the 4 single substitutions with the absence or presence of the 
H275Y mutation respectively. (C) The upper panel is the detection by anti-HA tag 
antibodies, and the lower is by anti-Actin antibodies. (D) The NA enzyme Km value of 
the rgBR/59/07 viruses of GA06-NA variants of the 4 single substitutions by enzyme 
kinetics assay. In all graphs, all values are the mean of 3 determinations ± SD. 
*, ** P<0.05 by t test when compared to GA06-wt or GA06-H275Y respectively. 
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Figure 3-12. The plaque morphology of rgBR/59/07 viruses by using variant GA06-
NA genes with different single amino acid substitutions. 
 
The plaque morphologies of the rgBR/59/07 viruses by using 10 variants of GA06-NA 
gene with 4 different single amino acid substitutions at the absence or presence of the 
H275Y mutation respectively. The mutation sites were shown above each image.  
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Regarding the enzyme activity of the GA06-NA variants of the single amino acid 
substitutions (Fig 3-11B), the H275Y mutation in the GA06-NA further decreased its 
intrinsically-low enzyme activity, as shown above. The R222Q or E329K substitution 
alone in the GA06-NA significantly increased enzyme activities (p<0.05), although to a 
smaller degree with the presence of the H275Y mutation. The V234M or D344N 
substitution alone in the GA06-NA slightly increased the enzyme activities, but at the 
presence of the H275Y mutation, both substitutions essentially alleviated the loss of the 
activity caused by H275Y mutation. 
 
We examined if the 4 amino acid substitutions in the GA06-NA increase the 
enzyme activity by the mechanisms we identified above and we firstly determined their 
effects on total protein expression level of the GA06-NA (Fig 3-11C). As shown above 
(Fig 3-3B), the protein expression level of GA06-NA was naturally-low, and the H275Y 
mutation in the GA06-NA aggravated the low expression level to an even lower level. 
Both R222Q and V234M substitution alone in the GA06-NA greatly increased the 
protein expression levels, even with the presence of the H275Y mutation. The E329K and 
D344N substitutions in the GA06-NA did not show any evident effect on protein 
expression. The results on protein expression were consistent with the roles of the 4 
markers we identified in the BR07-NA as above.  
 
We also tested the effects of the 4 substitutions in the GA06-NA on the enzyme 
Km value (Fig 3-11D). The Km value of the GA06-NA was intrinsically high as shown 
above (Fig 3-3D), and the H275Y mutation in the GA06-NA significantly raised the 
inherently high Km value to a higher degree (p<0.05). The R222Q, E329K and D344N 
substitutions alone in the GA06-NA significantly lowered the Km values respectively 
(p<0.05), but to a smaller degree with the presence of the H275Y mutation. The V234M 
substitution in GA06-NA did not show any impact on the Km value. The results on the 
enzyme Km value were consistent with roles of the 4 markers we identified in the 
BR07-NA as above.  
 
In conclusion, by using a reciprocal substitution strategy in the GA06-NA, we 
found that in the genetic background of the NC99-like NAs, the R222 and V234 two 
residues were responsible for the low level of NA protein expression, and the R222, E329 
and D344 three residues accounted for the low NA enzyme affinity to substrate binding. 
Furthermore, the NC99-like NAs were not only inherently low in quantity and quality 
due to the two groups of molecular markers, they also could not counteract the additional 
diminishing effects of the H275Y mutation on the protein expression and enzyme affinity 
and thus had no H275Y tolerance. On the other hand, each of the four reciprocal 
substitutions in the NC99-like NA partially but significantly increased the enzyme 
activity by increasing the protein quantity and/or quality. More importantly, the improved 
NA quantity and quality by the 4 reciprocal substitutions in the NC99-like NA partially 
counteracted the deleterious effects of the H275Y mutation on protein expression and 
enzyme affinity, and conferred at least partial degree of tolerance to the H275Y mutation. 
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Determination of the Timeline of Fixations of the Four Molecular Markers during 
Evolution of N1 NA Genes  
 
Now that we have identified that each of the 4 amino acid substitution (R222Q, 
V234M, K329E, D344N) in the NC99-like NA can partially but significantly improve the 
NA protein quantity and quality, we then sought to uncover the temporal sequence of the 
fixation of the four molecular markers into the NA gene during seasonal N1 evolution, 
and to understand if the sequential addition of all four molecular makers could fully 
reconstruct the quantity and quality of the NC99-like NAs to the level equivalent to those 
of the BR07-like NAs. 
  
The phylogenetic analysis with incorporation of a temporal scale and a 
probabilistic analysis  were used to determine the relative timeline of the fixation of each 
of the 4 molecular markers (Fig 3-13). The 354 position is of special interest for its 
reversion between the two lineages, so it was also included along with the other four 
positions for the analysis. First of all, the H275Y mutation appeared in a sporadic and 
random fashion before 2007. Since then, the H275Y mutation was fixed into the majority 
of the N1 populations especially during 2008~2009. Secondly, remarkably, all four 
amino acid substitutions emerged and were fixed into the N1 population prior to the 
fixation of the H275Y mutation; The 4 amino acid substitutions were fixed into the NA 
gene in a sequential manner in the order of V234M - R222Q - D344N - K329E.  Last, 
puzzlingly, a G354D substitution firstly occurred during the NA divergence at 2005, but 
later a D354G reversion arose, coincident with the fixation of H275Y mutation at 2008. 
Taken together, the timeline analysis is consistent with the previous lineage consensus 
residue analysis, but it is more informative as it provides evidence and insights about 
when the naturally-occurring oseltamivir-resistant H1N1 viruses emerged and how their 
emergence was associated with acquisition of the H275Y tolerance by the 4 molecular 
markers.  
 
 
Effects of Sequential Addition of the Four Molecular Markers into GA06-NA Genes 
on Protein Function and Expression 
 
To simulate the sequential fixation of 4 molecular markers during the NA 
evolution history, we sequentially placed the 4 amino acid substitutions into the 
GA06-NA gene one by one in an order indicated by the timeline analysis (V234M - 
R222Q - D344N - K329E), with the absence or presence of the H275Y mutation. Then 
we generated the reverse genetics viruses by using the 6 variants of the GA06-NA gene 
and compared them with GA06-NA and BR07-NA derived viruses as described above. 
As each of the four substitutions were added into GA06-NA sequentially, the virus 
plaque size and the enzyme activity increased accordingly in a progressive way (Fig 
3-14A, B, Fig 3-15), eventually to the degree fully equivalent to or even slightly higher 
than those of BR07-NA when the fourth substitution was added. With the presence of the 
H275Y mutation, the sequential addition of each substitution lead to the similar 
progressive increase of plaque size and enzyme activity as that in the absence of the 
H275Y mutation, but at a slightly small magnitude. More importantly, the sequential 
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Figure 3-13. The timeline of fixation of the 6 amino acid residue substitutions in the 
seasonal N1 NA genes.   
 
NA genes of representative 249 human seasonal H1N1 viruses were used for 
phylogenetic analysis. The tree was constructed by using the Bayesian simulations 
method. The probabilistic model was used to analyze of amino acid fixation by ancestral 
state reconstruction. The trunk color change shows that the average population possesses 
that particular amino acid residue indicated by the color code. Each tree is the same but 
shows the fixation of the amino acid residues for each of the 6 amino acid positions of 
NA proteins. The upper and lower arrow shows the time when the respective V234M and 
H275Y were fixed into the population.
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Figure 3-14.  Effects of sequential addition of four amino acid substitutions in the 
GA06-NA genes on plaque size of reverse-genetics viruses, NA enzyme activity, NA 
Km value and NA protein expression. 
 
(A) The plaque sizes of the rgBR/59/07 viruses by using 10 variants of GA06-NA genes 
with sequential addition of 4 different single amino acid substitutions with the absence or 
presence of the H275Y mutation respectively. The enzyme activities (B) and protein 
detection (C) of the 10 variant GA06-NA proteins with the sequential addition of 4 
substitutions with the absence or presence of the H275Y mutation respectively. (C) The 
upper panel is the detection by anti-HA tag antibodies, and the lower is by anti-Actin 
antibodies. (D) The NA enzyme Km value of the rgBR/59/07 viruses of GA06-NA 
variants with the sequential addition of the 4 substitutions by enzyme kinetics assay. The 
order of the sequential addition is as V234M + R222Q + D344N + K329E.  In all graphs, 
all values are the mean of 3 determinations ± SD. *, ** P<0.05 by t test when compared 
to GA06-wt or GA06-H275Y respectively. 
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Figure 3-15. The plaque morphologies of rgBR/59/07 viruses by using variant 
GA06-NA genes with sequential addition of the 4 amino acid substitutions. 
 
The plaque morphologies of the rgBR/59/07 viruses by using 10 variants of GA06-NA 
gene with 4 different single amino acid substitutions at the absence or presence of the 
H275Y mutation respectively. 
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addition at each step alleviated the degree of the loss of activity caused by the H275Y 
mutation, and the addition of all four substitutions into GA06-NA eventually led to only a 
marginal loss of the activity by H275Y mutation, equivalent to the minimal degree of 
activity loss in the BR07-NA by the H275Y mutation. 
 
We then examined the effects of the sequential addition of 4 amino acid 
substitutions in the GA06-NA on the protein expression and enzyme affinity (Fig 3-14C, 
D). The addition of the first two substitutions V234M and R222D into the GA06-NA not 
only greatly increased the level of NA protein expression to that of BR07-NA, but also 
effectively prevented the reduction of protein expression caused by the H275Y mutation. 
The addition of the next two substitutions V344D and E329K didn’t show any further 
impact on the protein expression. The first addition of V234M into the GA06-NA didn’t 
cause a measurable change of the enzyme Km value, but the following addition of 
R222D, V344D and E329K progressively and significantly reduced the enzyme Km 
value (p<0.05), eventually to a level equivalent to that of BR07-NA. Moreover, the 
sequential addition of the three substitutions also largely counteracted the diminishing 
effect by the H275Y mutation on enzyme affinity, and eventually controlled the level of 
enzyme affinity comparable to that of BR07-NA with the presence of the H275Y 
mutation.  
 
In summary, the sequential addition of the 4 amino acid substitutions (V234M - 
R222Q - D344N - K329E) greatly increased the NA protein quantity and then 
significantly increased the NA enzyme quality. There are 10 amino acid substitutions 
differentiating between the genotype of NC99-like and BR07-like NAs, but sequential 
addition of the 4 substitutions into the NC99-like NA was sufficient to reconstruct the 
NA protein quantity and quality to a level equivalent to those of the BR07-like NA. More 
importantly, the high NA protein quantity and quality by the 4 substitutions effectively 
counteracted the diminishing effects of the H275Y mutation on the protein expression 
and enzyme affinity, leading to only a marginal loss of the enzyme activity by the H275Y 
mutation, thus successfully conferring tolerance to the H275Y mutation. 
 
 
Determination of NA Tolerance to the H275Y Mutation in 2009 Pandemic H1N1 
Viruses 
 
In our previous study in Chapter 2, we characterized the transmissibility, growth, 
and NA kinetics of a wild-type (DM/524/09) and a H275Y mutant (DM/528/09) 2009 
pandemic H1N1 viruses (pH1N1), which only differed at the H275Y mutation. We found 
that the H275Y mutant pH1N1 virus had lower transmissibility in ferrets, delayed growth 
in cells and reduced NA affinity in vitro than the wild-type pH1N1, so we concluded that 
the H275Y mutant pH1N1 virus had lower fitness relative to the wild-type pH1N1 virus. 
In the present study, we identified that the NA tolerance to the H275Y mutation largely 
determined the virus fitness level of H275Y mutant viruses in the seasonal H1N1 virus 
lineage. Next, we sought to evaluate if and how the attenuated virus fitness in the H275Y 
mutant pH1N1 virus was associated with the NA H275Y intolerance.  
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NA gene comparison between the pandemic and seasonal H1N1 viruses. We 
first examined and compared the consensus sequences of NA genes between seasonal and 
2009 pandemic H1N1 viruses, specifically with a focus at the four amino acid positions 
with permissive residues for the H275Y mutation (Table 3-2). There is ~25% 
dissimilarity in amino acid residues compositions of the NA genes between seasonal 
H1N1 and pH1N1 viruses, which is associated with their distant ancestor in N1 gene 
evolution (22). We only listed the NA amino acid residues of pH1N1 viruses at the 10 
positions at which the residues differentiate the NA genes of two seasonal N1 lineages, 
which also showed great diversity from the seasonal lineages. By far, no predominant 
difference was found in the NA genes between the wild-type and H275Y mutant pH1N1 
viruses. With regards to the 4 amino acid positions permissive for the H275Y mutation in 
seasonal N1 lineage, the NA genes of pH1N1 viruses showed both conservation and 
diversity at the 4 positions. The NAs of pH1N1 viruses similarly encode V residue at the 
234 position as the NC99-like NAs, which was linked to the inherently-low NA protein 
expression. pH1N1 NAs encode N residue at the 344 site same as BR07-like NAs, which 
was linked the inherently-high NA enzyme affinity; but pH1N1 NAs encode a different N 
residue at 222 position other than the R or Q in seasonal NAs, and N residue at 329 
position other than the E or K in seasonal NAs. Considering the extensive diversity in the 
NA amino acid residue compositions between pH1N1 and seasonal H1N1 lineage, further 
extensive investigation is needed to characterize what roles these distinct molecular 
markers have in determining the NA protein quantity and quality respectively.  
 
NA activity, protein expression and enzyme affinity of the wild-type and 
H275Y mutant pandemic H1N1 viruses in vitro. Next, we evaluated if the NA protein 
of the pH1N1 virus have the tolerance to the H275Y mutation or not in the level of NA 
enzyme activity, protein expression level and enzyme affinity, in spite of the diverse NA 
amino acid residues. Two pairs of NA proteins, the wild-type and H275Y mutant of 
BR07-NA and GA06-NA were compared with the NAs of DM/524/09 and DM/528/09 
viruses (DM09-NA) respectively regarding to NA tolerance to the H275Y mutation.  
 
In the level of NA enzyme activity (Fig 3-16A), we compared the percentage loss 
of enzyme activity in each H275Y mutant NA proteins relative to its respective matching 
wild-type NA. The results showed the H275Y mutation caused loss of activity in the NA 
proteins of all three lineages, with lowest magnitude in the BR07-NA (~20%), and the 
greatest magnitude (~70%) in the DM09-NA which was even bigger than that in the 
GA06-NA (~50%). The results suggested that the DM09-NA was not able to tolerate the 
negative effects of the H275Y mutation on enzyme activity, with a huge loss of the 
activity in the H275Y mutant of DM09-NA. 
 
As for the NA protein expression (Fig 3-16B), the results showed that the protein 
expression level of the wild-type DM09-NA was inherently lower than that of the 
wild-type BR07-NA, and similar to that of the GA06-NA. The H275Y mutation further 
greatly reduced the inherently-low level of total protein expression of the DM09-NA and 
the GA06-NA, but hardly changed the level of the BR07-NA. The flowcytomerty 
confirmed that the cell surface accumulation of the DM09-NA was also greatly 
diminished by the H275Y mutation (Fig 3-16C). The results suggested that the  
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Figure 3-16. The NA activities, protein expression and enzyme Km values of the 
2009 pandemic H1N1 viruses. 
 
(A) The percentage loss of enzyme activities of the H275Y mutant NA of the DM09 
pandemic H1N1 virus relative to its wild-type NA, with comparison to the loss of activity 
in BR07 and GA06 NA protein pairs. (B) The detection protein expression of the 
wild-type and H275Y mutant of DM09-NA proteins, with comparison the loss of activity 
in BR07 and GA06 NA protein pairs. The upper panel is the detection by anti-HA tag 
antibodies, and the lower is by anti-Actin antibodies. (C) The surface protein 
accumulation of DM09-NA proteins by flowcytometry. Black line indicates the wild-type 
protein and red line indicates the H275Y mutant protein.  
 
 72 
DM09-NA was not able to tolerate the diminishing effects of the H275Y mutation on NA 
protein expression, with greatly reduced protein expression of the H275Y mutant of 
DM09-NA.  
 
As regards to NA enzyme affinity to substrate binding, a retrospective 
examination of the data in the previous and present studies (Table 2-1, Fig 3-7D) showed 
the wild-type DM09-NA exhibited a slightly higher Km value than the wild-type 
BR07-NA, suggesting its slightly lower enzyme affinity of substrate binding. The H275Y 
mutation further increased Km value of the DM/09-NA with a bigger magnitude than that 
of BR07-NA, but a smaller magnitude than that of GA06-NA. The results suggested that 
the DM09-NA had naturally relatively low enzyme affinity and the H275Y mutation 
further reduced its enzyme affinity. Although it is hard to determine if the DM09-NA had 
the tolerance to H275Y mutation on enzyme affinity level or not, as the reduction of the 
affinity was intermediate between the BR07-NA and GA06-NA, the H275Y mutation 
still had a negative effect on the enzyme affinity of the DM09-NA. 
  
In summary, the significant loss of the enzyme activity in the H275Y NA of the 
pH1N1 virus was caused by greatly reduced NA protein expression as well as reduced 
NA enzyme affinity by the H275Y mutation, which suggested the NA of pH1N1 virus 
now had no tolerance to the H275Y mutation. The NA intolerance to the H275Y 
mutation on the NA protein level correlated well with the lower virus fitness of the 
H275Y mutant pH1N1 virus than that of the wild-type pH1N1 virus, and further 
explained the delayed growth in cells and the transmissibility of the H275Y pH1N1 virus 
in ferrets.  
 
 
Discussion 
 
About the unorthodox naturally-occurring osletamivir-resistant seasonal H1N1 
viruses, one of biggest questions remained is what fundamental changes occurred in the 
NA genes and consequently in the NA proteins of the H1N1 viruses over the first decade 
of oseltamivir use. The findings of two permissive NA mutations enabling the evolution 
of H275Y mutant viruses significantly advanced our understanding of the defects caused 
by the H275Y mutation on the NA proteins, but it still left the question pending about 
what was the intrinsic changes or evolvement in the NA genes and proteins of the 
seasonal H1N1 viruses other than the defects caused by the H275Y mutation. This study, 
to our knowledge, is the first to understand how the genetic and phenotypic divergence of 
the NA proteins by themselves can allow the fixation of the H275Y mutation into the NA 
proteins during the NA evolution history, apart from understanding the defects caused by 
the H275Y mutation, which is underlying NA molecular basis of the naturally-occurring 
oseltamivir-resistant H1N1 viruses.  
 
By integrating NA genotype evolution with the consequent NA protein phenotype 
evolvement, we uncovered the at least some monumental “scenes” when the fundamental 
changes in NA genes and proteins occurred during the evolution of the seasonal H1N1 
viruses : 1) in the earlier years between 1999~2006, a lineage of human H1N1 viruses 
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called NC99-like viruses were the predominant circulating. The NC99-like NA proteins 
were inherently low in quantity and quality (protein expression and enzyme affinity), and 
the presence of the H275Y NA mutation could further diminish the inherently-low 
quantity and quality, which was destructive for the NA function. As the NC99-NAs 
cannot tolerate the presence of H275Y mutation on protein level, the H275Y mutant 
viruses had lower virus fitness level than the wild-type viruses. Owning to this reason, 
during that time, the NC99-like H275Y mutant viruses occasionally emerged under drug 
selection pressure, but the H275Y mutant viruses were soon extinguished by the 
wild-type viruses once the drug selection pressure was removed. 2) During the continuing 
H1N1 virus evolution, the NC99-like H1N1 viruses were gradually acquiring amino acid 
substitutions in NA genes as well as in HA genes. Starting from around 2003, the 
NC99-like NA genes sequentially acquired V234M and R222D substitution, which 
greatly enhanced the NA protein expression level; following that, the NA genes 
subsequently accumulated V344D and E329K substitutions, which significantly 
increased the NA enzyme affinity to substrate binding. 3) After the years, the sequential 
addition of a total of ten amino acid substitutions including the four function-altering 
substitutions into the NC99-like NA genes eventually led to emergence of a new lineage 
of NA genes and corresponding viruses at 2007, the BR07-like H1N1 viruses. The 
BR07-like NA proteins were naturally high in protein quantity and enzyme quality as a 
result of the four amino acid substitutions; more importantly, the high NA quantity and 
quality were able to counteract the negative effects of the H275Y mutation on the protein 
expression and enzyme affinity, and the function level of the BR07-like NA proteins was 
largely preserved with only a marginal loss; as the BR07-like NA proteins can tolerate 
the presence of the H275Y mutation on the protein level, the BR07-like H275Y mutant 
viruses retained a virus fitness level comparable to the wild-type viruses; thus they were 
able to continue circulation with wild-type viruses in the absence of the drug selection 
pressure until 2009 season before swine-origin pandemic influenza viruses took over the 
world. 
 
In our opinion, we stress the NA genetic divergence from NC99-like into 
BR07-like H1N1 viruses including the acquisition of the 4 molecular markers in the first 
place was associated with NA protein antigenic drift. Among the 10 positions at which 
the amino acid differentiates the two NA lineages, 3 positions (222, 249, 344) correspond 
to antibody recognition sites in the N2 NA protein (130-132) and the mutations at these 
three positions (Q222R, 249G, N344D) in the NA of BR/59/07 virus affected the 
reactivity of the different anti-sera to the virus in NA inhibition assay (133). The 329 
position was also suggested as a potential subdominant conserved epitope because 
E329K mutation in the NA of BR/59/07 virus was very important for the NA protein 
recognition by the human sera (133). It is uncertain if other 6 positions are also involved 
in antigenic sites and further understanding of N1 NA protein antigenic sites is needed. 
Nevertheless, among the 4 molecular markers we identified, three of them (222, 344, 
329) has been showed to be involved in NA antigenic determinants. In the NA molecular 
structure, all these three positions are at the surface of NA globular head distant from the 
NA active site, and they are all at the opposite side to the tetramer interface (Fig 3-2) 
(133). Theoretically, the structure locations of these three positions potentially allow their 
access to antibody or substrate binding. We are uncertain how to connect the 
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simultaneous changes in both NA antigencity and NA enzyme activity caused by the 
same amino acid residues in molecular level, and precise NA structures with different 
residue substitutions are required for answers to this question.  
 
It should be stressed that the natural force driving the divergence of NA genes of 
the H1N1 viruses most likely is the host immunity against NA protein. The host 
immunity can target the virus surface protein HA and NA during infection and herd 
immunity against the two proteins accumulates over a time of circulation of the viruses. 
To evade the herd immunity against the proteins, both HA and NA genes constantly 
evolves by acquiring mutations at the antigenic sites, known as antigenic drift (134). On 
the other hand, an intriguing hypothesis about NA evolution is that NA genes may 
co-evolve with HA genes (27). HA proteins may be subject to more host immunity 
pressure than NA proteins, as HA protein binds to the sialic acid-containing receptors and 
neutralization of HA proteins by host immunity can annul the virus replication in hosts. 
Considering the receptor-binding activity of HA and opposite receptor-destroying activity 
of NA, the fast evolving HA genes may necessitate co-evolution of NA genes to acquire 
an optional HA-NA balance for efficient virus replication and transmission. Some studies 
have showed that the phylogeny of the HA genes exhibited the same cluster pattern as the 
NA genes in the seasonal H1N1 viruses (63-65). The matched cluster patterns of the HA 
and NA genes may reflect the paralleled co-evolution of the two genes and matched 
function levels of the two proteins in the viruses. Nevertheless, the NA divergence of 
NC99-like to BR07-like firstly is associated with antigenic drift, and the genetic changes 
of the NA gene may result in potential changes in other protein phenotypes, such as 
protein expression and function identified in our case.  
 
 It also should be stressed that the accumulation of the four NA molecular markers 
during the natural NA gene divergence from NC99-like into BR07-like is most likely just 
fortuitously beneficial for the H275Y mutation. The four molecular markers can 
determine the low or high quantity and quality of NA proteins of the two lineages, but the 
terms of “low” or “high” are only relative between the two lineages. NA proteins neither 
being “low” nor “high” is a defect for the proteins to function as a part of whole 
infectious virus particle. In the present study, the wild-type NC99-like virus and 
BR07-like virus the virus exhibited the equivalent growth and transmissibility in the 
naive ferrets, which suggested that NC99-like viruses were not inferior to BR07-like 
viruses in the naïve hosts in terms of infectivity and transmissibility in spite of their 
“low” NA quantity and quality, and vice versa. The sustained circulation of the 
NC99-like viruses from 1999~2006 also suggests that the “low” NA quantity and quality 
is not a defect for the viruses themselves. The extinguishment of the NC99-like viruses 
by replacement of the BR07-like viruses primarily was the result of antigenic drift due to 
the accumulated herd host immunity against the NC99-like viruses over the extended 
circulation. BR07-like NA proteins being “high” quantity and quality are only 
fortuitously beneficial or “permissive” for the tolerance of the H275Y mutation. Only 
when the H275Y mutations were introduced into the NA protein, the H275Y mutation 
had differential effects on the NAs proteins, then the superiority of NA proteins regarding 
to the tolerance to the H275Y mutations can be separated. The “low” quantity and quality 
of the NC99-like NAs cannot tolerate the H275Y mutation, but the “high” quantity and 
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quality of the BR07-like NAs can tolerate the H275Y mutation. In other words, if the 
H275Y mutation had never emerged, the quantity or quality of the NAs would not have 
made a difference for the infectivity and transmissibility of the viruses. Concisely, the 
four NA molecular markers we identified here are 1) the residues associated with NA 
protein antigenic drift, 2) the residues associated with NA function in terms of protein 
quantity and enzyme quality, and 3) the residues associated with the tolerance to the 
H275Y mutation on NA proteins. 
  
In addition to the four NA molecular markers as described above, the NA 354 
position is of a unique genotype and functional role during the NA evolution of the H1N1 
viruses. Regarding the genotype of the position, during the NA divergence from the 
NC99-like into the BR07-like lineage, the amino acid residues were firstly substituted as 
G354D; then within the BR07-like lineage, it was exactly reversed as D354G in the 
majority of the H275Y mutant viruses, but remained unchanged as D in all the wild-type 
viruses within the lineage. As regards to its functional role, the D354G slightly increased 
the NA activity in the BR07-NA, which is exactly opposite to other four substitutions in 
the BR07-NA (from BR07-like to NC99-like) that all reduced the NA activity. Moreover, 
unlike the other four positions, the D354G somehow increased the NA activity but not 
through the change in protein expression or enzyme affinity. By our results, it remains 
unknown why the NC99-like NAs sequentially acquired the four substitutions to increase 
their NA activity, but then adopted G354D which apparently functioned opposite to NA 
activity. In spite of the enigmatic initial G354D substitution during the lineage switch, the 
later D354G reversion coinciding with H275Y mutation within the BR07-lineage seemed 
to have further increased the enzyme activity of H275Y mutant NAs and thus have 
repaired the marginal loss of NA activity caused by the H275Y mutation, which suggests 
that the later D354G reversion is also a beneficial mutation for the NA function in the 
H275Y mutant viruses. 
  
In the timeline of the fixation into NA genes, especially relative to the fixation of 
the H275Y mutation, the D354G reversion is of unique standing different from the other 
four molecular markers in N1 evolution history. In the timeline the four molecular 
markers arose sequentially between 2002~ 2006 during the NA divergence toward the 
BR07-like lineage, and the puzzling G354D substitution occurred around 2005~2006 at 
later stages of the divergence while the D354G reversion coincided or closely followed 
the fixation of H275Y mutation within the BR07-like lineage at 2008. By the integration 
of their relative fixation time and the respective function of the five molecular makers, 
we are able to further differentiate the unique role of the D354G reversion from the other 
four molecular markers. From a point of view of the molecular evolution of multiple 
mutations (67;135), the later D354G reversion can be better described as a 
“compensatory” mutation, which followed the major functional mutation (the H275Y 
mutation in this case) and it might be selected to aim to repair the function damage 
caused by the major functional mutation. Whereas the other four molecular markers 
rather better be classified as “permissive” residues, which occurred initially prior to the 
major functional mutation (the H275Y mutation), but were fortuitously beneficial for the 
major functional mutation.  
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The NA tolerance to the H275Y mutation at the protein level conferred by both 
the “permissive” residues and the “compensatory” mutation had profound ramification on 
virus fitness level. It is worth noting that virus fitness describes its adaptation or relative 
ability to produce infectious progeny in a host (39). A key concept about virus fitness is 
“relative”. Although originally a growth competition experiment between different 
viruses is used to define the fitness level of a virus relative to another virus (39), now, as 
an alterative, a comparative experiment between different viruses generally can be used 
to describe the fitness level of a virus relative to another virus. In our discussion, the 
“relative” is between wild-type and H275Y mutant viruses. The comparative virus 
infectivity and transmissibility etc all can demonstrate the virus fitness level relative to 
each other. In previous report at 2002, an H275Y resistant variant exhibited severely 
compromised replication and virulence both in vitro and in vivo compared with the 
wild-type virus (54;55), suggesting compromised fitness of the H275Y virus, presumably 
a NC99-like virus, relative to the wild-type virus. While in more recent studies, the 
replication of the recent BR07-like H275Y mutant viruses was not impaired in cells and 
ferrets compared to the wild-type viruses (61), suggesting uncompromised fitness of the 
viruses relative to the wild-type viruses. In our present study, we explicitly demonstrated 
that the replication and transmissibility of the NC99-like H275Y viruses in ferrets was 
significantly attenuated, while those of the BR07-like H275Y viruses were minimally 
altered, when compared with those of their counterpart wild-type viruses. The results 
clearly suggested the distinct fitness level of the H275Y mutant viruses relative to the 
corresponding wild-type viruses in the two lineages. The present study is closely 
correlated with the previous reports, which strongly supported that the NA intolerance or 
tolerance to the H275Y mutation in protein level largely determined the fitness outcome 
of the H275Y mutant viruses relative to the wild-type virus.  
 
The viral fitness of H275Y mutant viruses relative to wild-type viruses also can 
be illustrated by epidemiology data about their respective prevalence in circulation. The 
circulation prevalence of different viruses can be an ultimate manifestation of the virus 
fitness relative to each other in nature. Based on the surveillance studies of NA inhibitor 
susceptibility, between 1999~2006, there were extremely low prevalence of H275Y 
mutant influenza viruses among the globally collected influenza virus isolates (from 
0~1.7%) (32;46;48), suggesting that the H275Y mutant viruses had lower fitness 
advantage than the wild-type viruses and thus were extinguished from circulation at the 
time. However, between 2007 to 2009 pre-pandemic season, the H275Y mutant viruses 
were detected of global high prevalence in the context of absence of the drug treatment 
(45;56), even with a trend to override the wild-type viruses to become the dominant 
viruses, suggesting that the H275Y mutant viruses had equivalent or even higher fitness 
advantage than the wild-type viruses and thus were sustained in circulation. Notably, the 
timeline of the contrasting prevalence level of H275Y mutant viruses is also in 
accordance with the timeline of the circulation of NC99-like and BR07-like H1N1 
viruses, which also in accordance with our findings that the distinct fitness level of 
H275Y mutant viruses in the two lineages. 
 
With the identification of the NA molecular basis including both “permissive” 
markers and “compensatory” mutations in the naturally-occurring H275Y resistant 
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viruses, a retrospective look allows us to have a better understanding about the variations 
of the transmissibility of the H1N1 viruses in ferrets. In the BR07-like group, both 
HW/28/07 and rgBR/59/07-NAH275Y H275Y mutant viruses exhibited slightly delayed 
direct-contact transmission but essentially uncompromised transmissibility compared to 
the wild-type virus. Now the delay can be correlated to a common feature in their 
genotypes that both viruses possessed all 4 permissive markers but lacked the 
compensatory mutation D354G in their NA protein. The NY/3467/09 virus H275Y 
mutant also exhibited slightly delayed direct-contact transmission and this virus had the 
lowest NA enzyme affinity among the tested BR07-like viruses. Now both phenotypes 
can be correlated to the absence of the permissive D344N in its NA protein, although it 
had acquired the 3 permissive markers and the compensatory mutation. Both the 
NY/1672/09 and rgBR/59/07-NAH275Y+D354G H275Y mutant viruses exhibited the 
transmissibility equivalent to the wild-type virus in terms of efficiency and dynamics, 
which now can be correlated to the possession of all 4 permissive markers and the 
compensatory mutation in their NA proteins. In the NC99-like group, the severely 
attenuated transmissibility of GA/20/06 H275Y mutant virus now can be explained by the 
absence of entire 4 permissive markers in its NA protein. The MI/03/02 H275Y mutant 
virus also exhibited greatly attenuated transmissibility, which can be associated with the 
absence of the two permissive markers in its NA protein. This virus had acquired two 
permissive markers R222Q and D344N in its NA gene and its NA enzyme activity was 
the highest in the tested NC99-like NAs, so its attenuated transmissibility suggested that 
partial acquisition of the permissive markers was not sufficient to tolerate the negative 
effects of the H275Y mutation, and all four permissive markers might be required for the 
full tolerance to the H275Y mutation. 
  
The contrasting difference in the transmissibility of two aberrant H1N1 viruses 
NY/3467/09 and MI/03/02 viruses also suggested that there might be a function hierarchy 
among the four NA permissive molecular markers in terms of their permissive degree to 
the H275Y mutation. The residues composition at the four positions in the NA genes of 
NY/3467/09 and MI/03/02 viruses is aberrant from the sequential addition order 
suggested by our analysis (V234M - R222Q - D344N - K329E). The transmissibility of 
the NY/3467/09 virus was essentially uncompromised only with early delay, in spite of 
the absence of the D344N substitution in its NA gene. However, the transmissibility of 
the MI/03/02 virus was still greatly attenuated in spite of the presence of the two 
permissive markers R222Q and D344N in its NA protein. The distinct transmissibility of 
the two viruses suggested that degree of the “permissiveness” of the four molecular 
markers to the H275Y mutation may be different, although each of them played a 
significant role in the NA protein function.  It also suggested that all four of them were 
required to confer NA protein full tolerance to the H275Y mutation to maintain unaltered 
virus fitness (transmissibility). By our results, although the D344N significantly increased 
the NA function, the D344N alone may only exert a small degree of “permissiveness” to 
the H275Y mutation as its absence in the NY/3467/09 virus seemed to have not 
attenuated the transmissibility of the viruses, and its presence in the MI/03/07 virus 
seemed to have not rescued the transmissibility of the virus. The functional hierarchy of 
the four permissive mutations doesn’t necessarily correlate with the temporal sequence of 
the fixation of the four mutations, and further elucidations are warranted.  
 78 
With regards to the temporal sequential order for the four permissive molecular 
markers, we are uncertain of the underlying mechanism that prompted the first selection 
of the V234M during the NA divergence from NC99-like to BR07-like lineage. We 
showed that the V234M could increase the NA activity by increasing the NA protein 
expression, and all other three activity-increasing NA molecular markers appeared after 
the V234M. Apparently, the first appearance of V234M substitution made the NA protein 
promiscuous for more subsequent substitutions, especially the accumulation of 
activity-increasing NA substitutions. The underlying mechanism for such molecular 
selection is to be elucidated.  
 
We also point out that the NA molecular basis most likely is not the only 
molecular basis in the naturally-occurring H275Y resistant H1N1 viruses and we do not 
exclude the possible roles of other proteins in the emergence and spread of the naturally 
resistant H1N1 viruses. During 2008~2009, especially at the 2009 pre-pandemic season, 
the epidemiology data showed a trend that H275Y mutant viruses were overriding the 
wild-type viruses and becoming the dominant circulating viruses(45;56), suggesting that 
the H275Y mutant viruses had acquired better fitness including higher transmissibility 
than the wild-type viruses at the time. In the present study, we also noticed that both the 
NY/1602/09 and rgBR/59/07-NAH275Y+D354G H275Y mutant virus possessed the four 
permissive markers and the compensatory mutation, but their transmissibility had subtle 
differences: the NY/1692/07 virus had apparently faster transmission dynamics than the 
wild-type virus, but the later had the same transmission as the wild-type virus. Therefore, 
although our findings of the NA molecular basis largely explain why the 
rgBR/59/07-NAH275Y+D354G virus was not compromised compared to the wild-type 
viruses, it cannot explain why the NY/1692/09 virus exhibited even higher 
transmissibility than the wild-type virus, which is exactly in line with the trend of H275Y 
mutant viruses in 2009 season. It suggests that the naturally resistant viruses could have 
acquired more advantageous fitness through other mechanisms potentially by other 
proteins, which made them even more “fit” than wild-type viruses and overriding in 
circulation. Other studies have shed some clues, such as some HA amino acid 
substitutions promoting the replication of the resistant viruses, and some intra-subtype 
inter-clade segment reassortment events associated with the naturally resistant viruses 
(65;66;136). Further studies of the molecular basis other than NA in the 
naturally-occurring resistant viruses are warranted. 
  
One important implication of this study is its relevance to the H275Y 
mutation-caused resistance in the currently circulating swine-origin 2009 pandemic 
H1N1 (pH1N1) viruses. As for the virus fitness of H275Y mutant pH1N1 viruses, our 
study showed that a H275Y mutant pH1N1 viruses exhibited lower fitness than its 
counterpart wild-type pH1N1 virus including its less efficient transmissibility in ferrets 
and delayed growth in cells. In the NA molecular level, the attenuated virus fitness was 
well explained by significantly reduced NA enzyme activity due to greatly diminished 
protein expression and reduced enzyme affinity. The results strongly suggested that the 
NA of the pH1N1 virus had little tolerance to the H275Y mutation. However, we want to 
be very cautious to extend our findings and definition of the H275Y tolerance to the 
pH1N1 NA. We have discovered the NA H275Y tolerance at the levels of NA enzyme 
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activity, NA protein expression and NA enzyme affinity in H1N1 viruses of different 
lineages, but a perceptive standard needs to be further explored about how much degree 
of loss of activity, protein expression or enzyme affinity caused by the H275Y mutation 
can be defined as between tolerance and intolerance to the H275Y mutation. In the case 
of the NA of the H275Y mutant pH1N1 virus, the greatly reduced protein expression was 
rather conspicuous and could be easily defined as the intolerance to the H275Y at the 
protein expression level, but the magnitude of decrease of the enzyme affinity was 
between those of the BR07-like viruses and the NC99-like viruses, thus the conclusion 
remained ambiguous about the intolerance or tolerance to the H275Y at the enzyme 
affinity level. Moreover, with regards to the NA molecular basis for the tolerance to the 
H275Y mutation, we found the four permissive molecular markers (V234M, R222Q, 
D344N, K329E) and one compensatory mutation (D354G) in the NA genes seasonal 
H1N1 viruses. As seasonal N1 genes and 2009 pandemic N1 genes had distant ancestors 
(22), the questions remains uncertain if these markers play the same roles in NA proteins 
of pH1N1 viruses or if other amino acid residues can play similar roles. In the pH1N1 
viruses, we have seen the difficulty to answer the questions, because the NAs showed 
diverse amino acid residues at some positions other than the ones we identified in 
seasonal NAs. How these variant amino acid residues can affect the NA protein 
expression or function warrants additional studies. 
  
Our findings about NA tolerance to the H275Y mutation also have implication on 
the surveillance monitoring of the NA inhibitor resistance, especially the H275Y 
mutation-caused resistance. Our study underlines the necessity of not only continuous 
monitoring of drug resistance rates and but also characterization of evolving NA proteins. 
Our study showed that the H275Y mutant pH1N1 virus had lower fitness than the 
wild-type pH1N1 virus due to the NA intolerance to the H275Y mutation at the protein 
expression level, which is still in line with the low the detection rate (1~3.5%) of H275Y 
mutant pH1N1 viruses in surveillance studies so far (73). However, some studies have 
found un-attenuated H275Y mutant pH1N1 viruses in animal models (87;88), and several 
cases have identified community-transmitted H275Y mutant pH1N1 viruses (73;75-78). 
In view of the precedent example of how the wild-type seasonal H1N1 viruses became 
the naturally-occurring oseltamivir-resistant H1N1 viruses by acquisition of only the four 
“permissive”  molecular markers, it can be foreseen that the pH1N1 viruses also become 
the same naturally resistant through a similar NA evolution path. The question if pH1N1 
viruses have started its path to become naturally resistant needs to be further evaluated. 
Ideally, we need closely monitor pH1N1 NA genotype divergence and investigate the 
corresponding changes in NA protein phenotypes. If the genotype of pH1N1 NA were 
found diverged, any big conspicuous changes associated with the genetic change 
including the NA activity, protein expression and enzyme affinity should raise an alarm 
about their possible acquisition of tolerance to the H275Y mutation. Further studies of 
these newly isolated H275Y mutants of H1N1/2009 viruses are warranted, and the 
community-transmitted H275Y mutant pH1N1 viruses will be of special merit for the 
investigation. 
  
In summary, the present study uncovered how the NA proteins of the seasonal 
H1N1 viruses diverged during the evolution in terms of timeline, protein level attributes, 
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and more importantly, the tolerance to the H275Y NA mutation. This study is of 
significance to understand the NA molecular basis for the emergence and spread of the 
naturally-occurring oseltamivir-resistant H1N1 viruses, and of important implication on 
the surveillance monitoring of the virus susceptibility to NA inhibitors. Current epidemic 
viruses continue evolving under selection pressure, therefore, such monitoring is essential 
for public health, as NA inhibitors remain the primary therapeutic option for influenza 
virus infection. 
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CHAPTER 4.    METHODS 
 
 
Compounds 
 
The NA inhibitors oseltamivir carboxylate ([3R,4R,5S]-4-acetamido-5-amino-3-
[1-ethylpropoxy]-1-cyclohexene-1-carboxylic acid) and zanamivir (4-guanidino-
Neu5Ac2en) were provided by Hoffmann-La Roche, Ltd. (Basel, Switzerland). The 
compounds were dissolved in distilled water and aliquots were stored at –20 °C until the 
time of use. 
 
 
Cells 
 
Madin-Darby canine kidney (MDCK) cells and human embryonic kidney cells 
transformed with large T antigen (293T cells) were obtained from American Type 
Culture Collection (ATCC, Manassas, VA). MDCK cells were maintained in minimal 
essential medium (MEM) supplemented with 5% fetal bovine serum (FBS), 5 mM 
L-glutamine, 0.2% sodium bicarbonate, 100 U/ml penicillin, 100 ?g/ml streptomycin 
sulfate, and 100 ?g/ml kanamycin sulfate. 293T cells were maintained in opti-MEM 
(Invitogen) supplemented with 5% FBS and antibiotics as above.  MDCK cells 
transfected with cDNA encoding human 2,6-sialyltransferase (MDCK-SIAT1 cells) were 
kindly provided by Dr Mikhail N. Matrosovich and maintained as described previously. 
Baby Hamster Kidney (BHK) cells were kindly provided by Dr. Charles Russell and 
maintained as described previously (137). The Normal Human Bronchial Epithelial 
(NHBE) cells (Lonza, Basel, Switzerland) were cultured on an air-liquid interface in 
12-well plates and the infection with influenza viruses was described as previously (138). 
For growth curve, the inoculums were added to the apical surface of cells and were 
removed after 1 h of incubation at 37 ?C. Apical supernatants containing progeny viruses 
were collected by adding fresh medium into apical compartment 30 mins prior to the 
indicated time point and stored at –70°C for further titration in MDCK cells All the cell 
lines were maintained in a humidified atmosphere of 5% CO2 at 37 ºC. 
 
 
Viruses 
  
A panel of pandemic H1N1 and seasonal H1N1 influenza viruses of which the 
NA genes were previously sequenced and published on Genebank was chosen for the 
studies (Table 2-1 and Table 3-2). Among them, pandemic A/Denmark/524/2009 virus 
(DM/524/09) and A/ Denmark/528/2009 virus (DM/528/09) were provided by Statens 
Serum Institute, Copenhagen, Denmark. A/New York/3467/2009 virus (NY/3467/09) and 
A/New York/1692/2009 virus (NY/1692/09) were provided by Wadsworth center of the 
New York state department of health. Wild-type or NA H275Y mutant of 
A/Mississipii/03/2002 virus (MI/03/02) was provided by the Neuraminidase Inhibitor 
Susceptibility Network.  All the rest of viruses such as A/Brisbane/59/2007 virus 
(A/BR/59/09), A/Hawii/28/2008 virus (HW/28/08), A/New Jersey/15/2007 virus 
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(A/NJ/15/07), A/Georgia/17/2006 virus (GA/17/06), A/Georgia/20/2006 virus 
(GA/20/06), A/Memphis/13/2006 virus (MEM/13/06) etc viruses were provided by U.S 
Centers for Disease Control and Prevention. Stocks of the H1N1 viruses were prepared in 
MDCK cells. Upon receiving the viruses, all strains of virus underwent a limited number 
of (1~2) passages in MDCK cells to maintain their original properties. 
 
 
Virus Sequence Analysis 
 
Viral RNA was isolated by using the RNeasy Mini kit (Qiagen, Valencia, CA). 
Samples were reverse-transcribed and analyzed by PCR using primers specific for the 
NA gene segment, as described previously (139). Sequencing was performed by the 
Hartwell Center for Bioinformatics and Biotechnology at St. Jude Children’s Research 
Hospital. The DNA template was sequenced by using rhodamine or dRhodamine dye 
terminator cycle-sequencing Ready Reaction kits with AmpliTaq DNA polymerase FS 
(Perkin-Elmer, Applied Biosystems, Inc., Foster City, CA) and synthetic 
oligonucleotides. Samples were analyzed in a Perkin-Elmer Applied Biosystems DNA 
sequencer (model 373 or 377). DNA sequences were completed and edited by using the 
Lasergene sequence analysis software package (DNASTAR, Madison, WI).  
 
 
Plasmid Construction and Site-directed Mutagenesis 
 
The full length cDNA of 8 segments of BR/59/07 virus, and NA segments of 
GA/17/06 and GA/20/06 viruses were cloned into the pHW2000 plasmid vector for 
generation of reverse-genetics viruses in cells, as described previously (140). The 
respective mutations indicated in the results were introduced into the corresponding NA 
genes by using QuickChange site-directed mutagenesis (Stratagene, La Jolla, CA) and 
confirmed by Sanger sequencing. Selected NA genes listed in the results were also coned 
into the pCAGGS plasmid vector for expression of recombinant proteins in cells, as 
described previously (137). The HA epitop-tag sequence were added into the primer 
sequences to express the epitop-tagged NA protein by the vector. 
 
 
Generation of Reverse-genetics Influenza Viruses 
 
Reverse-genetics viruses were rescued by transfecting the PHW2000 plasmids 
containing 8 influenza segments into 293T/MDCK cells co-culture, as describe 
previously (141). Variant NA segments listed in the results were used together other 7 
segments from BR/59/07 virus respectively for rescuing the viruses. One passage of the 
rescued supernatant in MDCK cells (at MOI of 0.001~0.01) were used to prepare stocks 
of all reverse-genetics viruses.  
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Generation and Detection of Recombinant NA Proteins 
 
Recombinant NA proteins were generated by transfecting the respective pCAGSS 
plasmids into BHK cells, as described previously (137), and the protein expression was 
detected by western blot or flowcytometry. Generally, for the proteins which needed 
comparison among them, the same amount of each pCAGGS plasmid was transfected 
into respective wells of BHK cells in parallel. Then the cell pellet was harvested at same 
time in parallel, usually 24 hour post transfection for further analysis. For following 
analysis, the same amount of cells were used and assayed in parallel. Anti-HA epitope 
monoclonal antibodies (Sigma) were used for the detection of the recombinant proteins in 
flowcytometry or webstern blot, as described previously (142) . Anti-Actin monoclonal 
antibodies were used for detection of ?-Actin (Sigma) in the cells for normalization 
purpose. The pCAGGS plasmids of different NA gene variants are as indicated in the 
results. 
 
 
Determination of Infectivity of Influenza Viruses 
 
The 50% tissue culture infectious dose (TCID50) was determined in MDCK cells. 
The cells were infected with serial log dilutions of the stock viruses, incubated for 1 h at 
37ºC, washed, and overlaid with infection medium (MEM with 0.3% BSA and 1 ?g/ml 
TPCK-trypsin). Infection of cells was determined by hemagglutination assay (HI) after 
incubation for 3 d at 37°C, and TCID50 was calculated by the Reed-Muench method. The 
plaque assay was used to determine the plaque forming unit (pfu) in a virus stock. 
Confluent MDCK cells were incubated for 1 h at 37ºC with 10-fold serial dilutions of 
virus in 1 ml of infection medium. The cells were then washed and overlaid with freshly 
prepared MEM containing 0.3% BSA, 0.9% bacto-agar, and 1 μg/ml TPCK trypsin. The 
plaques were visualized after incubation at 37ºC for 3 d by staining with 0.1% crystal 
violet solution containing 10% formaldehyde. 
 
 
Replication Kinetics 
 
Single-step or multi-step growth curves were generated for influenza viruses in 
MDCK cells. For single-step growth curve, confluent cell monolayers were infected with 
viruses at a multiplicity of infection (MOI) of ~ 2.0 PFU/cell. After incubation, the cells 
were washed with 0.9% aqueous NaCl solution (pH 2.2) to remove free infectious virus 
particles and then were washed twice with phosphate-buffered saline (PBS) to adjust the 
pH. Supernatants were collected 2, 4, 6, 8, 10 and 12 h p.i. and stored at –70°C for 
titration. To generate multi-step growth curves, MDCK cells were infected with viruses at 
an MOI of 0.001 PFU/cell. Supernatants were collected 12, 24, 36, 48, 60 and 72 h p.i. 
and stored at –70°C for titration. 
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Virus Susceptibility to NA Inhibitors 
 
The viral NA activity was determined first by a modified fluorometric assay using 
the fluorogenic substrate 2’-(4-methylumbelliferyl)-?-D-N-acetylneuraminic acid 
(MUNANA) (Sigma-Aldrich). The fluorescence of the released 4-methylumbelliferone 
was measured in a Synergy 2 multi-mode microplate reader (BioTek) using excitation 
and emission wavelengths of 360 and 460 nm, respectively. The drug concentration 
required to inhibit 50% of the NA enzymatic activity (IC50) was determined by plotting 
the percent inhibition of NA activity as a function of compound concentration calculated 
in the GraphPad Prism 4 software from the inhibitor-response curve. The NA 
inhibitor-sensitive A/Fukui/20/04 (H3N2) influenza virus was included in every plate for 
comparison. 
 
 
NA Enzyme Kinetics 
 
All H1N1 viruses were standardized to an equivalent dose of 106.0 PFU/ml. We 
measured NA enzyme kinetics at pH 6.5 with 33 mM 2-(N-Morpholino) ethanesulfonic 
acid hydrate (MES; Sigma-Aldrich), 4 mM CaCl2, and MUNANA with a final substrate 
concentration of 0 to 800 ?M. The reaction was conducted at 37°C in a total volume of 
50 ?l, and the fluorescence of released 4-methylumbelliferone was measured every 60 sec 
for 60 min in a Synergy 2 multi-mode microplate reader (BioTek) using excitation and 
emission wavelengths of 360 and 460 nm, respectively. The Km and Vmax were 
calculated by fitting the data to the appropriate Michaelis-Menten equations by using 
nonlinear regression in the GraphPad Prism 4 software.  
 
 
Virus Transmission Experiments in Ferrets 
 
The animal work with the pandemic H1N1/2009 influenza viruses was performed 
in an animal biosafety level 3+ (ABSL3+) laboratory approved by the U.S. Department 
of Agriculture. The animal work with seasonal H1N1 influenza viruses was conducted in 
ABSL2+ laboratory under applicable laws and guidelines and after approval from the St. 
Jude Children’s Research Hospital Animal Care and Use Committee. The ferrets for the 
pandemic H1N1 virus study were were obtained from the ferret breeding program at St. 
Jude Children’s Research Hospital. The ferrets for the seasonal H1N1 virus study were 
obtained from Triple F farm. All ferrets were 4-5 months of age and were sero-negative 
for contemporary influenza A H1N1 and H3N2 viruses and for influenza B viruses. 
Ferrets were firstly housed in the isolators in and monitored for 3-5 days to establish 
baseline body temperature and overall health. Donor ferrets were initially housed 
separately from contact ferrets.  
 
The experiment settings were slightly different between the studies for pandemic 
and seasonal H1N1 viruses. For the study of pandemic viruses, one donor ferrets were 
lightly anesthetized with isoflurane and inoculated with 106 TCID50 of each of the 
pandemic H1N1 viruses in 1.0 ml sterile PBS respectively. One donor ferret was 
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inoculated with 106 TCID50 of a mixture of A/DM/524/09 and A/DM/528/09 viruses (1:1 
infectivity ratio). After the donor ferrets were confirmed to shed virus on day 2 p.i. by the 
Directigen Flu A+B quick test (BD, Franklin Lakes, NJ), each was then housed with 2 
naïve direct-contact ferrets in the same cage. Two additional recipient ferrets were placed 
in an adjacent cage isolated from the donor’s cage by a two layers of wire mesh (~5 cm 
apart) that prevented physical contact but allowed the passage of respiratory droplets. 
Borazine gun (Zero Toys, Concord, MA ) tested that the airflow was non-directional 
inside the isolator. Thus, the transmission setting was 1 donor + 2 direct-contact + 2 
respiratory-droplet recipient ferrets for each tested pandemic virus.  
 
For the study of seasonal viruses, three donor ferrets were inoculated with 105 
TCID50 each of the seasonal H1N1 viruses in 1.0 ml sterile PBS respectively as the 
results listed. Then at day 1p.i, each was then housed with 1 naïve direct-contact ferrets in 
the same cages. One additional naïve ferret was placed in an adjacent cage separated by 
double layers of perforated dividers (~5cm apart) for the purpose of respiratory-droplet 
transmission. The cages were oriented to direct the airflow from the donor cage side to 
the respiratory-droplet recipient cage side. Thus the transmission setting was 3 replicates 
of 1 donor + 1 direct-contact + 1 respiratory-droplet recipient ferret for each virus. For 
both studies, Ferret nasal wash samples were collected at day1 p.i and the following 
every other day from day 2 p.i for 14 days. Ferret weight, temperature and other clinical 
signs were recorded daily for 21 days. Body temperature was measured by subcutaneous 
implantable temperature transponders (Bio Medic Data Systems Inc, Seaford, DE).  
 
 
Collection and Titration of Nasal Wash Samples 
 
Nasal washes were collected from donor and recipient ferrets on day 1, 2, 4, 6, 8, 
10, 12, and 14 p.i. by flushing ferret both nostrils with 1.0 ml PBS, and TCID50 titers 
were determined in MDCK cells. Inflammatory cell counts were determined for the 
pandemic virus study. Briefly, the nasal washes were centrifuged at 2000 rpm for 5 min. 
The pellet was resuspended in PBS, and the total cell number was counted in a 
hemacytometer under light microscopy.  Inflammation was defined as a cell count ? 10 
times the baseline count which was determined before the inoculation or exposure. 
 
 
Serologic Tests 
 
Serum samples were collected from ferrets 3 weeks after virus inoculation, treated 
with receptor-destroying enzyme, heat-inactivated at 56 °C for 30 min, and tested by HI 
assay with 0.5% packed Turkey red blood cells (TRBC).   
 
 
Quantitative Single Nucleotide Polymorphism Assay  
 
The quantitative single nucleotide polymorphism (SNP) assay was performed to 
determine the proportion of wild-type or H275Y mutant viruses in mixed sample for the 
 86 
pandemic virus study as described previously (138), with slight modification. Briefly, an 
NA fragment (nucleotide 673 to 1034) containing the codon at NA 275 position was 
amplified by RT-PCR. Single nucleotide primer extension was performed using a 
SNaPshot kit (ABI) per the manufacturer’s protocol. A extension probe was used to 
detect the first nucleotide of NA 275 codon. After the SNaPshot reaction, the product was 
analyzed by ABI 3730xl capillary electrophoresis instrument (ABI) per the 
manufacturer’s protocol. Data were analyzed by using ABI GeneMapper software.  
 
 
Statistical Analysis   
 
The unpaired t-test or analysis of variance (ANOVA) was used for all 
comparisons, if the significance was indicated in the result description, then p<0.05. 
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